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Introduction	  and	  purposes.	  
	  
Multiple	  myeloma	  (MM)	  is	  a	  heterogeneous	  disease.	  The	  discovery	  of	  a	  class	  of	  small	  non-­‐
coding	  RNAs	  (miRNAs)	  has	  revealed	  a	  new	  level	  of	  biological	  complexity	  underlying	  the	  
regulation	  of	  gene	  expression.	   It	  may	  be	  possible	  to	  use	  this	   interesting	  new	  biology	  to	  
improve	  our	  ability	  to	  risk	  stratify	  patients	  in	  the	  clinic.	  
	  
	  
Methods	  and	  experimental	  design.	  
	  
We	  performed	  global	  miRNA	  expression	  profiling	  analysis	  of	  163	  primary	  tumors	  included	  
in	   the	   UK	   Myeloma	   IX	   clinical	   trial.	   miRNA	   expression	   profiling	   was	   carried	   out	   using	  
Affymetrix	  GeneChip	  miRNA	  2.0;	   expression	  values	   for	  847	  hsa-­‐miRNAs	  were	  extracted	  
using	   Affymetrix	   miRNA	   QC	   tool	   and	   RMA-­‐normalized.	   There	   are	   also	   153	   matching	  
samples	  with	  gene	  expression	  profiles	  (GEP)	  and	  72	  matching	  cases	  with	  genotyping	  data	  
available	  for	  integrative	  analyses.	  GEP	  was	  generated	  on	  Affymetrix	  HG-­‐U133	  Plus	  2.0	  and	  
the	  expression	  values	  were	  RMA	  normalized;	  genotyping	  was	  performed	  on	  Affymetrix	  
GeneChip	  Mapping	  500K	  Array	  and	  the	  copy	  number	  values	  were	  obtained	  using	  GTYPE	  
and	  dChip	  and	  were	  inferred	  against	  normal	  germ-­‐line	  counterpart	  for	  each	  sample.	  
	  
	  
	  	   3	  
Results.	  
	  
Firstly	  we	  have	  defined	  8	  miRNAs	  linked	  to	  3	  Translocation	  Cyclin	  D	  (TC)	  subtypes	  of	  MM	  
with	  distinct	  prognoses,	  including	  miR-­‐99b/let-­‐7e/miR-­‐125a	  upregulation	  and	  miR-­‐150/miR-­‐
155/miR-­‐34a	  upregulation	  in	  unfavourable	  4p16	  and	  MAF	  cases	  respectively	  as	  well	  as	  miR-­‐
1275	  upregulation	  and	  miR-­‐138	  downregulation	  in	  favourable	  11q13	  cases.	  The	  expression	  
levels	   of	   the	   miRNA	   cluster	   miR-­‐99b/let-­‐7e/miR-­‐125a	   at	   13q13	   have	   been	   shown	   to	   be	  
associated	   with	   shorter	   progression	   free	   survival	   in	   our	   dataset.	   Interestingly	  
unsupervised	   hierarchical	   clustering	   analysis	   using	   these	   8	   miRNAs	   identified	   two	  
subclusters	  among	  11q13	  cases,	  which	  have	  differential	  effect	  on	  overall	  survival	  (OS).	  We	  
then	  evaluated	  the	  association	  of	  miRNA	  expression	  with	  OS	  and	  identified	  3	  significantly	  
associated	   miRNAs	   (miR-­‐17,	   miR-­‐18	   and	   miR-­‐886-­‐5p)	   after	   multiple	   testing	   corrections,	  
either	  per	   se	  or	   in	   concerted	   fashion.	   	  We	  went	  on	   to	  develop	  an	  “outcome	  classifier”	  
based	  on	  the	  expression	  of	  two	  miRNAs	  (miR-­‐17	  and	  miR-­‐886-­‐5p),	  which	  is	  able	  to	  stratify	  
patients	  into	  three	  risk	  groups	  (median	  OS	  19.4	  months	  vs	  40.6	  months	  vs	  65.3	  months,	  
log-­‐rank	  test	  P	  =	  0.001).	  The	  robustness	  of	  the	  miRNA-­‐based	  classifier	  has	  been	  validated	  
using	   1000	   bootstrap	   replications	   with	   an	   estimated	   error	   rate	   of	   1.6%.	   The	   miRNA-­‐
stratified	   risk	   groups	   are	   independent	   from	   main	   adverse	   fluorescence	   in	   situ	  
hybridization	   (FISH)	   abnormalities	   (1q	   gain,	   17p	   deletion	   and	   t(4;14)),	   International	  
Staging	  System	  (ISS)	  and	  Myeloma	  IX	  treatment	  arm	  (intensive	  or	  non-­‐intensive).	  
	  
Using	  the	  miRNA-­‐based	  classifier	  in	  the	  context	  of	  ISS/FISH	  risk	  stratification	  showed	  that	  
it	  can	  significantly	  improve	  the	  predictive	  power	  (likelihood-­‐ratio	  test	  P	  =	  0.0005)	  and	  this	  
classifier	   is	   also	   independent	   from	   GEP-­‐derived	   prognostic	   signatures	   including	   UAMS,	  
IFM	   and	   Myeloma	   IX	   6-­‐gene	   signature	   (P	   <	   0.002).	   Integrative	   analyses	   didn't	   show	  
enough	   evidence	   that	   the	  miRNAs	   comprising	   the	   classifier	  were	   deregulated	   via	   copy	  
number	  changes;	  however,	  our	  data	  supported	  that	  the	  mir-­‐17~92	  cluster	  was	  activated	  
by	  Myc	   and	   E2F3,	   highlighting	   the	   potential	   importance	  of	  Myc/E2F/miR-­‐17~92	   negative	  
feedback	   loop	   in	   myeloma	   pathogenesis.	   We	   developed	   an	   approach	   to	   identify	   the	  
putative	   targets	   of	   the	   OS-­‐associated	   miRNAs	   and	   show	   that	   they	   regulate	   a	   large	  
number	  of	  genes	   involved	   in	  MM	  biology	  such	  as	  proliferation,	  apoptosis,	  angiogenesis	  
and	  drug	  resistance.	  




In	  this	  study	  we	  developed	  a	  simple	  miRNA-­‐based	  classifier	  to	  stratify	  patients	  into	  three	  
risk	  groups,	  which	  is	  independent	  from	  current	  prognostic	  approaches	  in	  MM	  such	  as	  ISS,	  
FISH	  abnormalities	  and	  GEP-­‐derived	  signatures.	  The	  miRNAs	  comprising	  the	  classifier	  are	  
biologically	  relevant	  and	  have	  been	  shown	  to	  regulate	  a	  large	  number	  of	  genes	  involved	  
in	  MM	  biology.	  This	   is	   the	   first	   report	   to	  show	  that	  miRNAs	  can	  be	  built	   into	  molecular	  
diagnostic	  strategies	  for	  risk	  stratification	  in	  MM.	  
	  















Multiple	  myeloma	   (MM)	   is	   an	   incurable	   disease	   characterized	  by	  heterogeneous	  
molecular	   features,	   presentation	   and	   outcome,	   and	   accounts	   for	   up	   to	   10%	   of	  
haematological	   malignancies,	   with	   an	   incidence	   in	  Western	   countries	   of	   about	   3-­‐5	   per	  
100,000.	   The	   average	   age	   of	   onset	   is	   70	   years.1-­‐3	   MM	   affects	   antibody-­‐secreting	   bone	  
marrow	  (BM)	  plasma	  cells	  (PCs)	  and	  shows	  a	  wide	  clinical	  presentation	  ranging	  from	  the	  
presumed	   pre-­‐malignant	   condition	   of	   monoclonal	   gammopathy	   of	   undetermined	  
significance	   (MGUS)	   to	   smoldering	   MM,	   truly	   overt	   and	   symptomatic	   MM,	   and	   extra-­‐
medullary	  myeloma	  or	  plasma	  cell	  leukemia	  (PCL).	  To	  date,	  MM	  diagnosis	  is	  based	  on	  the	  
criteria	  established	  by	  the	  International	  Myeloma	  Working	  Group	  in	  2003,4	  subsequently	  
updated	   in	  2009.5	  MM	   is	  defined	  as	   symptomatic	  upon	   the	  simultaneous	  occurrence	  of	  
clonal	   plasma	   cells	   >10%	   in	   BM	   biopsy,	  monoclonal	   serum	   (or	   urinary)	   paraprotein	   and	  
related	   organ/tissue	   impairment.	   Patients	   are	   staged	   according	   to	   Durie	   and	   Salmon	  
criteria6	   or,	   now	  widely	   increasingly	   and	  more	   effectively,	   to	   the	   International	   Staging	  
System	  (ISS)7	  that	  consider	  serum	  β2-­‐microglobulin	  and	  albumin	  levels.	  Indeed,	  ISS	  could	  
be	   considered	   a	   prognostic	   index	   rather	   than	   a	   true	   staging	   system,	   as	   it	   is	   a	   valid	  
measure	   of	   risk	   of	   progression	   and	   short	   outcome	   for	   patients	  with	  MM	  presentation,	  
and	   is	  not	   strictly	  a	  measure	  of	   tumor	  burden	  or	  extent	  unlike	   staging	   systems	  used	   in	  
other	  cancers.	  
MM	  is	  characterized	  by	  a	  remarkable	  genomic	  instability	  that	  encompasses	  ploidy	  
	  	   6	  
and	  structural	   rearrangements	   (Figure	   1).8,9	  Such	  a	  genomic	   instability,	  mediated	  by	  the	  
interaction	   with	   environmental	   factors	   and	   combined	   with	   the	   normal	   physiological	  
processes	   that	   lead	   to	   the	   generation	   of	   antibody	   diversity,	   substantially	   contribute	   to	  




Based	   on	   their	   large	   distribution	   in	   most	   clonal	   cells,	   the	   chromosomal	  
translocations	  generated	  by	  aberrant	  class-­‐switch	  recombination	  have	  been	  suggested	  to	  
be	   initiating	   events	   occurring	   early	   in	   the	   disease	   process.	   As	   a	   result	   of	   these	  
translocations,	   several	   genes	   are	   aberrrantly	   placed	   under	   the	   control	   of	   the	   strong	  
Figure	  1.	  Model	  for	  molecular	  pathogenesis	  of	  MGUS	  and	  MM	  (from	  Kuehl,	  M	  and	  
Bergsagel,	  PL,	  2012,	  J	  Clin	  Invest).	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enhancers	  of	  the	  immunoglobulin	  (IGH@)	  gene	  loci,	  leading	  to	  their	  ectopically	  increased	  
expression.	   As	   regards	   chromosomal	   numeric	   imbalances,	   approximately	   half	   of	   MM	  
tumors	  are	  hyperdiploid	  with	  non-­‐random	  trisomies	  of	  odd	  chromosomes	  3,	  5,	  7,	  9,	  11,	  15,	  
19	  and	  21,	   together	  with	  a	   low	  prevalence	  of	   chromosomal	   translocations	   involving	   the	  
IGH@	   on	   chromosome	   14q32.4.	   The	   remaining	   tumors	   are	   referred	   as	   non-­‐hyperdiploid	  
and	   are	   frequently	   associated	   with	   the	   constitutive	   activation	   of	   CCND1	   (11q13),	   CCND3	  
(6p21),	  MAF	   (16q23),	  MAFB	   (20q11),	  or	  FGFR3/MMSET	   (4p16.3)	  genes	  as	  a	   result	  of	   IGH@	  
translocations.	  	  	  
The	  mechanisms	  underlying	  this	  dichotomic	  pattern	  have	  not	  been	  elucidated	  but	  
hyperdiploid	   patients	   have	   a	   generally	   better	   prognosis,	   whereas	   the	   t(4;14)	   and	   the	  
t(14;16)	  are	  associated	  with	  a	  poor	  prognosis.	  Other	  genetic	  abnormalities	  (e.g.,	  N-­‐/K-­‐RAS	  
and	   BRAF	   mutations,	   inactivation	   of	   p53	   and/or	   del(17)(p13),	   Myc	   deregulation)	  
characterize	   mainly	   the	   non-­‐hyperdiploid	   fraction	   of	   MM	   cases	   and	   are	   specifically	  
associated	  with	  advanced	  stages	  of	   the	  disease.8-­‐10	  Therefore,	   the	  understanding	  of	  the	  
molecular	   bases	   of	   the	   disease	   represents	   an	   important	   step	   to	   dissect	   the	   clinical	  
heterogeneity	  of	  the	  disease	  and	  the	  variety	  of	  clinical	  presentation.	  
Noteworthy,	  although	  several	  promising	  studies	  report	   the	  relationship	  between	  
drugs	  effect	  and	  MM	  subtypes,	  the	  treatment	  of	  MM	  has	  so	  far	  been	  largely	  independent	  
of	  any	  of	  the	  main	  molecular	  or	  genetic	  features,	  and	  is	  related	  to	  other	  factors	  (e.g.	  the	  
age	  of	  onset,	  being	  considered	  younger	  patients	  those	  with	  MM	  presentation	  before	  65	  
ys);	  a	  targeted	  therapy	   is	  a	  early	  desirable	  scenario	  but	  currently	  still	  not	  tangible.11	  The	  
conventional	   long-­‐lasting	   anti-­‐myeloma	   therapy	   (alkylators	   and	   corticosteroids,	   with	   a	  
median	  post-­‐treatment	  overall	  survival	  of	  3-­‐4	  years)	  have	  been	  first	  implemented	  by	  high-­‐
dose	   therapy	   followed	   by	   autologous	   stem	   cell	   transplantation	   (ASCT,	   median	   OS	   5–7	  
years)	   and	   then,	   over	   the	   last	   few	   years,	   by	   the	   new-­‐generation	   treatments:	   the	  
proteasome	   inhibitor	   bortezomib	   and	   the	   immunomodulatory	   drugs	   thalidomide	   and	  
lenalidomide	   has	   been	   the	   cornerstone	   of	   improving	   the	   outcome	   of	   patients	   with	  
myeloma.12	  However,	  there	  is	  still	  a	  lack	  of	  effective	  therapies	  targeting	  the	  deregulated	  
biological/molecular	   pathways	   specifically	   associated	  with	   subsets	   of	   the	   disease.	   Only	  
the	   recent	   updates	   in	   myeloma	   treatment	   guidelines	   have	   partially	   introduced	   risk	  
stratification	   and	  molecular	   features	   as	   factors	   for	   choosing	   therapy.	   For	   instance,	   the	  
Mayo	   Clinic	   has	   developed	   a	   risk-­‐stratification	   model	   termed	   Mayo	   Stratification	   for	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Myeloma	   and	   Risk-­‐adapted	   Therapy	   (mSMART),	   which	   dissects	   patients	   into	   high-­‐risk	  
(bortezomib-­‐based	   treatments)	   and	   standard-­‐risk	   categories	   (lenalidomide	   and	  
dexamethasone	  for	  patients	   ineligible	  for	  ASCT).	  Patients	  with	  deletion	  of	  chromosome	  
13	   or	   hypodiploidy	   by	   conventional	   cytogenetics,	   t(4;14),	   t(14;16)	   or	   17p-­‐	   by	   molecular	  
genetic	  studies,	  or	  with	  a	  high	  plasma	  cell	   labeling	  index	  (3%	  or	  more)	  are	  considered	  as	  
high-­‐risk	  myeloma.13	  The	  unfavorable	  prognostic	  value	  of	  t(4;14)	  and	  deletion	  of	  17p	  is	  in	  
line	   with	   other	   studies	   that	   introduced	   serum	   β2-­‐microglobulin	   as	   discriminant	   and	  
independent	  variable	  in	  association	  with	  genomic	  alterations.14	  
The	  recent	  advances,	  mainly	  based	  on	  next	  generation	  sequencing	  procedure	  that	  
allows	   the	   high-­‐throughput	   screening	   of	   somatic	   mutations	   and	   genetic	   changes,	   are	  
contributing	   to	   delineate	   a	   further	   complex	   scenario	   of	   the	   disease	   (Figure	   2).	   From	  
several	  studies	  analyzing	  the	  MM	  genome	  emerged	  that	  mechanisms	  with	  a	  likely	  role	  in	  
the	  biology	  of	  myeloma	  (e.g.,	  NF-­‐kB	  activation)	  may	  be	  candidate	  to	  broad	  roles	  by	  virtue	  
of	  mutations	  in	  multiple	  members	  of	  these	  pathways.15-­‐19	  The	  genomic	  landscape	  of	  MM,	  
in	  particular,	  pointed	  to	  a	  number	  of	  recurrently	  mutated	  genes	  (the	  TP53	  gene,	  occurring	  
in	  almost	   10%	  patients;	   the	  KRAS,	  NRAS	  and	  BRAF	  genes	   included	   in	   the	  MAPK-­‐pathway,	  
overall	   occurring	   in	   more	   than	   half	   tumors;	   the	   functionally	   uncharacterized	   FAM46C	  
mapped	  at	   1p;	   	   the	  exonuclease	  encoding	  DIS3	  gene;	   the	  TRAF3,	  BIRC2,	  BIRC3,	   and	  CYLD	  
genes	  associated	  with	  the	  regulation	  of	  the	  NF-­‐kB	  signaling	  pathway),	  whose	  overall	  rate	  
encompasses	  up	  to	  more	  than	  80%,	  virtually	  the	  totality,	  of	  MM	  patients	  (Figure	  3),	  and	  
that	   are	   candidate	   as	   causal	   drivers	   of	   the	   disease.	   The	   general	   notion	   underlying	   the	  
progression	  of	  myeloma	   is	   that	  multiple	  mutations	   in	  different	  pathways	  collaborate	   to	  
deregulate	  the	  intrinsic	  biology	  of	  the	  PCs;	  recent	  data	  suggest	  that	  clonal	  progression	  is	  
the	   key	   feature	   of	   MM	   evolution	   into	   aggressive	   disease,	   being	   the	   invasive	   clinically	  
predominant	  clone	  typical	  of	  MM	  already	  present	  at	  earlier	  stages	  and	  gradually	  selected	  
by	   step-­‐by-­‐step	   treatments.	   It	   is	   becoming	   commonly	   accepted,	   in	   fact,	   that	   the	  
molecular	   events	   acquired	   during	   myeloma	   progression	   are	   not	   acquired	   in	   a	   linear	  
fashion	  but	  instead	  through	  branching,	  nonlinear	  pathways:9	  in	  line	  with	  this,	  therefore,	  it	  
is	   now	   evident	   that	   the	   genetic	   complexity	   of	   myeloma	   is	   based	   on	   intraclonal	  
heterogeneity	  at	  the	  level	  of	  a	  myeloma-­‐propagating	  cell.18,20-­‐22	  Unavoidably,	  this	  has	  (and	  
will	   have)	   important	   effects	   on	   the	   clinical	   application	   of	   both	   standard	   and	   targeted	  
treatment	  strategies,	  to	  which	  NGS	  might	  significantly	  contribute.20,23	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Figure	  2.	  Circos	  plot	  showing	  the	  key	  translocations,	  copy	  number	  abnormalities	  and	  
mutations	  frequently	  found	  in	  myeloma.	  The	  chromosomes	  are	  arranged	  clockwise	  
around	  the	  circle.	  	  IGH@	  translocations	  are	  represneted	  by	  inner	  lines	  emerging	  from	  
chromosome	  14	  to	  the	  respective	  partner	  chromosomes.	  Copy	  number	  data	  are	  shown	  
inside	  the	  circle:	  red	  indicates	  deletions,	  blue	  gains	  and	  black	  normal	  copy	  number.	  Genes	  
targeted	  by	  deletions	  and/or	  mutations	  are	  labelled	  on	  the	  outside	  of	  the	  circle	  and	  
coloured	  according	  to	  the	  abnormality	  as	  in	  the	  top-­‐left	  legend	  (from	  Morgan,	  GJ,	  2013,	  
Nature	  Rev).	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Figure	  3.	  Exemplar	  heatmap	  representing	  individual	  mutations	  in	  a	  cohort	  of	  MM	  patient	  
samples	  from	  Multiple	  Myeloma	  Resarch	  Consortium	  dataset	  (light-­‐bliue:	  missense;	  red:	  
non-­‐sense;	  orange:	   frame-­‐shift;	  yellow:	   in	   frame	   in-­‐dels;	  brown:	  other	  non	  synonimous).	  
On	  the	  left,	  the	  histogram	  shows	  the	  number	  of	  mutations	  in	  each	  gene;	  the	  percentages	  
represent	   the	   fraction	   of	   tumors	   with	   at	   least	   one	   mutation	   in	   the	   specified	   gene	  
(modified	  from	  Lohr,	  et	  al,	  2014,	  Cancer	  Cell).	  
	  
Finally,	  it	  is	  also	  worth	  mentioning	  that	  a	  characteristic	  feature	  of	  myeloma	  cells	  is	  
the	   requirement	   for	  an	   intimate	   relationship	  with	   the	  BM	  microenvironment	   (Figure	  4),	  
where	   the	   occurrence	   of	   specialized	   plasma	   cell	   niches	   facilitates	   the	   growth	   of	   the	  
myeloma	  clone.	  Several	  intercellular	  stimuli	  have	  been	  so	  far	  charcterized	  that	  sustain	  PC	  
development	   in	   the	   BM:	  
some	  of	   the	   critical	   survival	  
and	  growth	  factors,	  such	  as	  
IL-­‐6,	   are	   produced	   by	  more	  
than	   one	   kind	   of	   BM	   cell.	  
External	   stimuli,	   such	   as	  
hypoxia	  and	   internal	   signals	  
that	   largerly	   involve	   (and	  
result	   from)	   MYC	  
dysregulation,	  stimulate	  the	  
secretion	   of	   factors,	   e.g.	  
HIF-­‐1α	  or	  the	  pro-­‐angiogenic	  
VEGF,	   which	   in	   turn	  
stimulate	   endothelial	   cells	  
to	  secrete	  IGF-­‐1.	  The	  altered	  
Figure	  4.	  The	  interactions	  of	  MM	  tumor	  cells	  with	  
the	   BM	   microenvironment	   (from	   Kuehl,	   M	   and	  
Bergsagel,	  PL,	  2012).	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bone	   remodeling,	   hallmark	   of	   MM	   disease,	   is	   the	   effect	   of	   an	   increase	   in	   osteoclast	  
activity	  –	  mediated	  by	  RANKL/RANK	  interactions,	  decreased	  osteoprotegerin	  (OPG),	  and	  
increased	  MIP-­‐1α	  –	  and	  a	  decrease	  in	  osteoblast	  activity	  –	  mediated	  by	  DKK1	  and	  IL-­‐3.	  The	  
increase	   in	   osteoclast	   activity	   stimulates	   the	   survival	   and	   growth	   of	  MM	   cells,	   at	   least	  
partially	   by	   increased	   IL-­‐6.10,24,25	   Acquiring	   independence	   of	   these	   interactions	   is	  
fundamental	  in	  the	  immortalization	  of	  a	  myeloma-­‐propagating	  cell.	  	  
	   Overall,	  MM	  poses	  a	  unique	  challenge	  for	  genotyping	  and	  expression	  profiling	  by	  
virtue	   of	   its	   inherent	   heterogeneity,	   with	   the	   aim	   of	   a	   fine	   stratification	   and	   early	  
identification	   of	   which	   patients	   are	   at	   risk	   of	   progression	   or	   relapse,	   or	   ultimately	   to	  
provide	  the	  most	  effective	  therapeutic	  regimen	  to	   individual	  patients.	  Nevertheless,	  the	  
complexity	  of	  the	  disease	  represents	  a	  serious	  obstacle	  to	  reaching	  these	  aims,	  which	  is	  
further	  issued	  by	  intrinsic	  limitations	  and	  variability	  of	  high-­‐throughput	  technologies.	  
Over	  the	  last	  few	  years,	  the	  high-­‐throughput	  microarray	  technologies,	  particularly	  
global	  gene	  expression	  (GEP)	  and	  genome-­‐wide	  DNA	  profiling	  (GWP),	  have	  been	  widely	  
used	  to	  investigate	  the	  genomic	  instability	  underlying	  the	  bio-­‐clinical	  heterogeneity	  of	  the	  
disease.	   Such	   approach	   led	   to	   promising	   results,	   either	   per	   se	   or	  when	   analyzed	   in	   an	  
integrated	  fashion.	  In	  addition,	  the	  recent	  discovery	  of	  microRNA	  and	  their	   involvement	  
in	  tumor,	  together	  with	  the	  application	  of	  microarray	  to	  define	  their	  expression	  profiling	  
is	  offering	  an	  unprecedented	  perspective	  of	  the	  involvement	  of	  non-­‐coding	  RNAs	  in	  MM	  
tumor.	  
microRNA	  
MicroRNAs	  (miRNAs)	  are	  small	  (18-­‐24	  nucleotides),	  evolutionarily	  conserved	  non-­‐
coding	  RNAs	  that	  bind	  to	  the	  3’untranslated	  region	  (UTR)	  of	  target	  mRNAs	  and	   lead	  to	  
translation	  repression	  or	  mRNA	  degradation	  (Figure	  5).26	  	  
They	   are	   transcribed	   by	   RNA	   polymerase	   II	   from	   genes	   located	   in	   extra-­‐	   or	  
intragenic	  genomic	  regions	  into	  primary	  precursors	  (pri-­‐miRNAs)	  of	  different	  lengths.	  The	  
expression	   of	   intronic	   miRNAs	   largely	   coincides	   with	   that	   of	   their	   corresponding	   host	  
genes,	   thus	   suggesting	   that	   they	   share	   the	   same	   regulatory	   sequences.27,28	   Pri-­‐miRNAs	  
are	  processed	  into	  secondary	  precursors	  that	  have	  a	  stem-­‐loop	  structure	  (pre-­‐miRNAs)	  of	  
approximately	   70	   nucleotides	   that	   are	   subsequently	   translocated	   to	   the	   cytoplasm	   by	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exportins,	   where	   they	   are	   further	   processed	   into	   18-­‐	   to	   24-­‐nucleotide	   duplexes	   by	   the	  
RNAase	   III	   enzyme	   DICER1.	   Only	   one	   strand	   (guide	   strand)	   is	   incorporated	   as	   mature	  
miRNA	  into	  the	  RNA-­‐induced	  silencing	  complex	  (RISC)	  that	  mediates	  target	  RNA	  cleavage	  
or	   translational	   inhibition;	   the	   other	   (passenger)	   strand	   is	   degraded.	   The	  RISC	   leads	   to	  
mRNA	   cleavage	   whenever	   the	   complementarity	   between	   the	   mature	   miRNA	   and	   the	  
3’UTR	   of	   the	   target	   mRNA	   is	   perfect;	   when	   the	   complementarity	   is	   partial,	   it	   inhibits	  
protein	  translation.	  The	  major	  component	  of	  the	  RISC	  is	  the	  Argonaute	  2	  (AGO2)	  protein,	  
which	  has	  RNA	  cleavage	  activity	  and	  is	  also	  involved	  in	  miRNA	  biogenesis.29	  
	   	  
Figure	  5.	  microRNA	  biogenesis	  (from	  Lionetti	  M,	  Agnelli	  L,	  et	  al.	  2012)	  
	  
One	   thousand,	   eight-­‐hundred	   seventy-­‐two	   human	   miRNA	   genes	   are	   currently	  
included	   in	   the	   Sanger	  miRNA	   registry	   (miRBase	   version	   20,	   June	   2013),	   a	   database	   of	  
miRNA	  sequences	  and	  annotations.	  A	  single	  miRNA	  can	  control	  the	  levels	  of	  hundreds	  of	  
different	   target	   genes,	   and	   multiple	   miRNAs	   can	   regulate	   a	   single	   mRNA.	   Various	  
interactions	  have	  so	  far	  been	  described,	  and	  a	  number	  of	  databases	  of	  the	  target	  genes	  
of	  each	  of	  the	  known	  miRNAs	  are	  now	  available.30	  It	  has	  been	  estimated	  that	  more	  than	  
60%	   of	   human	   protein-­‐coding	   genes	   are	   subject	   to	  miRNA	   regulation	   (Friedman	   et	   al.,	  
	  	   13	  
2009).	  Many	   of	   the	   known	  miRNAs	   are	   clustered	   in	   the	   genome,	   suggesting	   that	   they	  
might	  work	   in	  combination	   to	  achieve	   their	  biological	   function.	   	  Moreover,	  a	  very	   large	  
number	   of	   tools	   have	   been	   implemented	   as	   means	   of	   predicting	   targets	   based	   on	  
sequence	  affinity,	  thus	  leading	  to	  the	  predicted	  interactions	  that	  represent	  a	  strong	  basis	  
for	  further	  in-­‐vitro	  validation.31	  
There	   is	   strong	   evidence	   indicating	   that	   miRNAs	   play	   important	   roles	   in	   cell	  
processes	   such	   as	   proliferation,	   development,	   differentiation	   and	   apoptosis,32	   and	   it	   is	  
therefore	   not	   surprising	   that	   their	   expression	   is	   profoundly	   deregulated	   in	   human.33,34	  
The	  first	  direct	  link	  between	  miRNAs	  and	  cancer	  was	  highlighted	  by	  Calin	  et	  al.,	  that	  found	  
that	   the	  minimal	  deleted	   region	  of	   chromosome	   13q14	   in	   chronic	   lymphocytic	   leukemia	  
(CLL)	  contained	  the	  genes	  encoding	  miR-­‐15a	  and	  miR-­‐16,35	  and	  that	  the	  two	  miRNAs	  were	  
down-­‐regulated	   in	   over	   two-­‐thirds	   of	   the	   cases.	   Later,	   the	   same	   Authors	   also	  
demonstrated	   that	   the	   miRNAs	   target	   BCL2,	   an	   anti-­‐apoptotic	   oncogene	   that	   is	   often	  
over-­‐expressed	   in	   CLL.36	   Evidence	   that	   miRNAs	   play	   a	   causative	   role	   in	   tumorigenesis	  
have	   accumulated	   rapidly;	   transcriptional	   deregulations,	   epigenetic	   alterations,	  
mutations,	   DNA	   copy	   number	   abnormalities,	   and	   defects	   in	   the	   miRNA	   biogenesis	  
machinery	  are	  all	  mechanisms	  contributing	  to	  miRNA	  deregulation	  in	  cancer,	  either	  alone	  
or	   in	   combination.37	   In	   overall	   terms,	   the	   over-­‐expression	   of	   miRNAs	   targeting	   one	   or	  
more	   tumor	   suppressor	   genes	   (TSG)	   can	   inhibit	   anti-­‐oncogenic	   pathways,	   whereas	  
miRNAs	  defects	   in	   repressing	  one	  or	  more	  oncogenes	  may	   lead	   to	   a	  gain	   in	  oncogenic	  
potency.	   Furthermore,	   mutations	   in	   the	   sequence	   of	   mature	   miRNAs	   or	   in	   the	   seed-­‐
matched	   sequence	   of	   their	   target	  mRNAs	   can	   reduce	   or	   eliminate	   the	   repression,	   and	  
switch	  it	  towards	  other	  transcripts.38	  The	  oncogenic	  role	  of	  a	  number	  of	  miRNAs	  has	  been	  
experimentally	  demonstrated	  in	  various	  tumors,	  including	  hematological	  malignancies,	  as	  
is	  the	  case	  of	  the	  pro-­‐tumorigenic	  cluster	  miR-­‐17~92,39	  miR-­‐155,40	  and	  miR-­‐21.41	  Conversely,	  
other	   miRNAs	   such	   as	   those	   of	   let-­‐7	   family	   have	   tumor	   suppressor	   activity.42,43	   Global	  
miRNA	   expression	   profiling	   studies	   have	   revealed	   miRNA	   dysregulation	   in	   virtually	   all	  
types	   of	   cancer	   and	   highlighted	   the	   usefulness	   of	   miRNA	   profiling	   in	   diagnosis	   and	  
prognosis,	  and	   in	  predicting	  response	  to	  therapy.44-­‐50	   It	   is	  not	  surprising,	  therefore,	  that	  
miRNA	   expression	   profiles	   can	   also	   be	   used	   to	   classify	   cancer,	   often	   with	   a	   greater	  
degree	  of	  accuracy	  than	  traditional	  GEP	  (Lu	  et	  al.,	  2005;	  Calin	  &	  Croce,	  2006b).	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MicroRNA	  in	  multiple	  myeloma	  biology	  
The	  involvement	  of	  miRNAs	  in	  MM	  pathogenesis	  was	  first	  described	  by	  Pichiorri	  et	  
al.,	  who	  profiled	   the	  miRNA	  expression	  of	  PCs	   in	  a	   restricted	  series	  of	  normal	   subjects,	  
MGUS	  and	  MM	  samples,	  and	  a	  number	  of	  MM-­‐derived	  cell	   lines	  (HMCLs).51	  The	  analysis	  
led	   to	   the	   identification	  of	  different	  miRNA	  expression	  signatures	   in	  abnormal	  PCs	   that	  
were	  associated	  with	  tumor	  progression;	  in	  particular,	  miR-­‐181a	  (which	  is	  known	  to	  play	  a	  
role	  in	  B	  and	  T	  cell	  differentiation),	  the	  oncogenic	  cluster	  miR-­‐106b∼25	  (in	  particular	  miR-­‐
93,	   miR-­‐106b,	   and	   miR-­‐25),	   and	   miR-­‐21	   were	   all	   up-­‐regulated	   in	   the	   MGUS	   and	   MM	  
samples,	   whereas	  miR-­‐32	   and	   the	  miR-­‐17~92	   cluster	   (particularly	   miR-­‐19a	   and	  miR-­‐19b)	  
were	   significantly	   up-­‐regulated	  only	   in	   the	  MM	   samples,	   thus	   suggesting	   their	   possible	  
role	   in	   disease	   progression.	   The	   miR-­‐17~92	   cluster	   miRNAs	   have	   been	   recently	  
demonstrated	   as	   positively	  modulated	   by	  Myc	   and	   associated	  with	   poor	   prognosis	   (in	  
particular,	   high	   expression	   of	   miR-­‐17,	   miR-­‐20	   and	   miR-­‐92	   was	   linked	   to	   shorter	  
progression	   free	   survival).52	   Functional	   assays	   on	   HMCLs	   have	   related	   the	   deregulated	  
expression	  of	  some	  of	  these	  miRNAs	  to	  biological	  processes	  that	  are	  particularly	  relevant	  
in	  MM	  pathogenesis:	  miR-­‐181a	  and	  miR-­‐181b,	  the	  miR-­‐106b∼25	  cluster	  and	  miR-­‐32	  interact	  
with	  the	  3’UTR	  of	  PCAF	  gene,	  a	  regulator	  of	  TP53	  activity	  in	  myeloma	  cells,	  whereas	  miR-­‐
19a	  and	  miR-­‐19b	  target	  SOCS-­‐1,	  a	  negative	  regulator	  of	  the	  IL-­‐6R/STAT3	  pathway	  that	  may	  
therefore	  play	  a	  role	  in	  the	  anti-­‐apoptotic	  signal	  triggered	  by	  IL-­‐6.51	  The	  relevance	  of	  miR-­‐
21	   to	   MM	   was	   previously	   suggested	   by	   Loffler	   et	   al.,	   who	   demonstrated	   that	   miR-­‐21	  
transcription	   is	   controlled	   by	   IL-­‐6	   through	   a	   mechanism	   involving	   STAT3,	   and	   that	   its	  
ectopic	   expression	   gives	   independence	   of	   the	   IL-­‐6-­‐growth	   stimulus.53	  MiR-­‐21	   was	   then	  
very	   recently	   found	   to	   be	   involved	   in	   a	   positive	   regulatory	   loop	   with	   STAT3	   by	   direct	  
targeting	   the	   protein	   inhibitor	   of	   activated	   STAT3	   (PIAS3).54	   It	   has	   been	   additionally	  
reported	  that	  miR-­‐21	  expression	  was	  partially	  driven	  by	  NFkB	  signaling	  via	  myeloma	  cell	  
adhesion	   to	   BMSCs	   and	   that	   suppression	   of	  miR-­‐21	   expression	   contributed	   to	   sensitize	  
MM	  cells	  to	  dexamethasone	  and	  doxorubicin	  and	  reduce	  MM	  cells	  invasiveness.55	  Recent	  
findings	   suggest	   that	   miRNAs	   are	   key	   players	   in	   controlling	   cell	   proliferation	   and	  
differentiation	   by	   actively	   functioning	   in	   the	   TP53	   tumor	   suppressor	   network.56	   In	   the	  
context	  of	  MM	  (in	  which	  mutation-­‐	  induced	  TP53	  inactivation	  is	  rare),	  Kumar	  et	  al.	  found	  
that	   the	   expression	  of	   two	  miRNAs	   identified	   as	   TP53	   regulators	   (miR-­‐25	   and	  miR-­‐30d)	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was	   higher	   in	   MM	   patients	   than	   in	   healthy	   donors	   and,	   interestingly,	   that	   the	   TP53	  
transcript	  and	  miRNA	  levels	  were	  moderately	  inversely	  correlated.57	  The	  inhibition	  of	  the	  
two	  miRNAs	   in	   a	  MM	   cell	   line	  with	   a	   wt	   TP53	   gene	   increased	   TP53	   protein	   levels	   and	  
enhanced	  apoptosis.	  Pichiorri	  et	  al.	   investigated	  the	  TP53/MDM2	  autoregulatory	  loop	  by	  
exploiting	   a	   panel	   of	   HMCLs	   and	   primary	   tumors	   with	   or	   without	   inactivating	   TP53	  
mutations.58	  Using	  MDM2	  inhibitors,	  they	  found	  that	  miR-­‐192,	  miR-­‐194	  and	  miR-­‐215	  were	  
only	  up-­‐regulated	  in	  myeloma	  cells	  harboring	  a	  wt	  TP53,	  and	  demonstrated	  that	  they	  can	  
be	  considered	  as	  TP53	  targets.	  These	  miRNAs	  can	  affect	  TP53-­‐dependent	  MM	  cell	  growth	  
by	  inhibiting	  MDM2	  expression;	  in	  addition,	  miR-­‐192	  and	  miR-­‐215	  specifically	  targeted	  the	  
IGF	   pathway,	   thus	   preventing	   the	   enhanced	  migration	   of	   PCs	   into	   BM.	   These	   findings,	  
together	  with	   the	   evidence	   of	   hypermetylation	   of	   the	   promoter	   region	   of	   the	  mir-­‐194-­‐
2/192	  cluster	  probably	  leading	  to	  their	  down-­‐regulation	  in	  MM	  in	  comparison	  with	  MGUS	  
samples,	  are	  of	  particular	  interest	  as	  TP53	  function	  is	  retained	  in	  the	  majority	  of	  untreated	  
patients	  and	  it	  might	  be	  susceptible	  to	  successful	  modulation.59	  
	  
Recent	  studies	  have	  concentrated	  on	  the	  pathogenetic	  role	  of	  miR-­‐15a	  and	  miR-­‐16,	  
which	   are	   located	   at	   13q14	   chromosomal	   region,	   that	   is	   frequently	   deleted	   in	   CLL,	  MM	  
and	  MCL.	  These	  two	  miRNAs	  are	  abundantly	  expressed	  in	  multiple	  human	  tissues	  and	  are	  
involved	   in	  anti-­‐proliferative	  and	  pro-­‐apoptotic	   activities,	  which	   suggests	   that	   they	  may	  
represent	  candidate	  targets	  of	  the	  deletion.	  Roccaro	  et	  al.	  provided	  the	  first	  evidence	  of	  
the	   functional	   role	   of	   miR-­‐15a	   and	   miR-­‐16	   in	   MM	   by	   showing	   that	   the	   two	   miRNAs	  
regulate	  the	  proliferation	  and	  growth	  of	  HMCLs	  in	  vitro	  and	  in	  vivo	  by	  inhibiting	  a	  number	  
of	  molecular	  pathways,	  such	  as	  those	  involving	  AKT3,	  ribosomal	  protein	  S6,	  MAP	  kinases,	  
and	  the	  NF-­‐kB-­‐activator	  MAP3K7IP3.60	  Furthermore,	  miR-­‐15a	  and	  miR-­‐16	   inhibit	  MM	  cell-­‐
triggered	  endothelial	   cell	   growth	  and	  capillary	   formation	   in	   vitro	  and	   in	   vivo,	   and	  exert	  
their	  anti-­‐MM	  activity	  of	  inhibiting	  migration	  and	  growth	  of	  MM	  cells	  even	  in	  the	  context	  
of	   the	   BM	   milieu,	   thus	   overcoming	   the	   growth	   advantage	   normally	   conferred	   by	   BM	  
stromal	  cells.	  A	  possible	  explanation	  of	  this	  finding	  resides	  in	  that	  the	  suppression	  of	  miR-­‐
15a/16	   expression	   (possibly	   mediated	   by	   IL-­‐6	   secretion)	   represents	   one	   of	   the	  
mechanisms	   through	   which	   BM	   stromal	   cells	   provide	   survival	   support	   to	   MM	   cells.	  
Interestingly,	  Hao	  et	  al.	  reported	  that	  melphalan	  and	  bortezomib	  treatment	  up-­‐regulated	  
miR-­‐	   15a/16	   expression	   in	   MM	   cells,	   whereas	   the	   interaction	   of	   MM	   cells	   with	   BMSCs	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inhibited	   miR-­‐15a/16	   expression	   and	   suppressed	   apoptosis	   of	   MM	   cells	   induced	   by	  
cytotoxic	  agents.61,62	  These	  data	  strongly	  suggest	   the	   tumor	  suppressor	  activity	  of	  miR-­‐
15a	  and	  miR-­‐16,	  although	  their	   role	   in	  disease	  development	   in	  primary	  MM	  patients	  and	  
the	   impact	   of	   chromosome	   13	   deletion	   on	   their	   expression	   remain	   controversial.	   The	  
specific	  down-­‐regulation	  of	  miR-­‐15a	  and	  miR-­‐16	  (regardless	  of	  the	  status	  of	  chromosome	  
13)	   was	   the	   starting	   point	   for	   Roccaro’s	   study	   of	   their	   functional	   role	   in	   MM,60	   but	  
Pichiorri	   et	   al.	   found	   that	  miR-­‐15a	   (as	  well	   as	   other	  miRNAs	  mapped	   on	   13q)	  were	   up-­‐
regulated	   in	   MM	   PCs	   vs	   healthy	   PCs.51	   As	   discussed	   later,	   our	   group	   have	   found	   a	  
significant	   correlation	   between	   the	   expression	   of	  miR-­‐15a	   (as	  well	   as	  miR-­‐19a	   and	  miR-­‐
621)	  and	  alterations	   in	   the	  corresponding	  DNA	   locus	   in	  HMCLs	   (probably	  due	   to	  miRNA	  
over-­‐expression	   in	  aneuploid	  cell	   lines	  with	  more	   than	   two	  copies	  of	  chromosome	  13)63	  
but	  not	  in	  primary	  tumors,	  in	  which	  only	  the	  expression	  of	  miR-­‐17	  and	  miR-­‐20a	  (13q31)	  was	  
reduced	  in	  cases	  with	  13q	  deletion.64	  Other	  Authors	  have	  reported	  varying	  levels	  of	  miR-­‐
15a/1665	  as	  well	  as	  of	  miR-­‐17~9252	  expression	  in	  MM	  patients,	  regardless	  of	  chromosome	  
13	  status.	  Finally,	  Gutierrez	  et	  al.	   found	  that,	   like	  miR-­‐19a,	  miR-­‐19b	  and	  miR-­‐20a,	  miR-­‐15a	  
was	  down-­‐regulated	  in	  the	  patients	  carrying	  the	  RB	  deletion	  alone	  in	  comparison	  with	  the	  
normal	  PC	  samples	  or	  MM	  patients	  without	  this	  abnormality,66	  and	  Chi	  et	  al.	  reported	  the	  
down-­‐	   regulation	   of	   both	   miR-­‐15a/16	   and	   miR-­‐17~92	   cluster	   in	   del(13)	   cases.67	   Overall,	  
although	  there	  is	  evidence	  indicating	  that	  miR-­‐15a	  and	  miR-­‐16	  probably	  play	  a	  role	  in	  MM,	  
their	  relationships	  with	  MM	  biology	  and	  the	  13q14	  deletion	  remain	  to	  be	  clearly	  defined.	  
	  
MiRNA	  expression	  in	  different	  molecular	  types	  of	  MM	  
As	   stated	   above,	  MM	   is	   characterized	   by	   profound	   genomic	   instability	   involving	  
both	   numerical	   and	   structural	   chromosomal	   aberrations.	   A	   number	   of	   global	   gene	  
expression	   profiling	   (GEP)	   studies	   have	   clearly	   shown	   that	   distinctive	   gene	   expression	  
signatures	   are	   associated	   with	   the	   major	   molecular	   subtypes.68-­‐78	   Very	   recently,	   the	  
potential	  impact	  of	  MM	  genetic	  lesions	  on	  miRNA	  expression	  has	  also	  been	  investigated	  
using	  the	  same	  global	  analyses	  on	  the	  basis	  of	  evidence	  showing	  that	  genomic	  alterations	  
frequently	  deregulate	  miRNA	  expression	  in	  human	  cancer.79-­‐82	  
Applying	  an	  integrative	  genomic	  approach	  to	  a	  representative	  panel	  of	  16	  HMCLs	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and	  in	  19	  primary	  MM	  tumors,	  Lionetti	  et	  al.64	  found	  that	  a	  large	  number	  of	  miRNA	  genes	  
were	  located	  in	  genomic	  areas	  affected	  by	  allelic	  imbalances	  that	  may	  lead	  to	  significantly	  
altered	  expression	   levels:	   these	   include	  mir-­‐17	  and	  mir-­‐20a,	  which	  belong	  to	  a	  cluster	  at	  
13q31	  deleted	  in	  almost	  40%	  of	  patients;	  miR-­‐140-­‐3p	  at	  16q22.1,	  a	  region	  that	  is	  recurrently	  
involved	  in	  LOH	  and	  has	  prognostic	  and	  possible	  pathogenetic	  importance	  in	  myeloma;83	  
and	   a	   number	   of	   miRNAs	   located	   in	   odd-­‐numbered	   chromosomes	   involved	   in	  
hyperdiploidy.	  	  
Information	   concerning	  
the	  association	  between	  miRNA	  
expression	   and	   the	   major	  
genetic	   lesions	   in	   myeloma	  
(particularly	   chromosomal	  
translocations)	   is	   still	   limited	  
and	   partly	   controversial.	  
Lionetti	   et	   al.	   have	   provided	  
evidence	   that	   the	   miRNA	  
transcriptional	   profiles	   of	   40	  
MM	   samples	   significantly	  
grouped	   the	  patients	   according	  
to	  the	  proposed	  TC	  (translocation	  
and	   cyclin	   D)	   classification,	  
particularly	  with	  regard	  to	  t(4;14)	  
(TC4)	   and	   MAF-­‐translocated	  
(TC5)	  samples	  (Figure	  6).	  In	  line	  with	  the	  consistency	  of	  these	  signatures	  within	  groups,	  it	  
is	   worth	   noting	   that	   a	   leave-­‐one-­‐out	   cross-­‐validation	   approach	   to	   the	   dataset	   showed	  
that	  13	  miRNAs	  could	  classify	  the	  large	  majority	  of	  samples	  (up	  to	  80%).64	  and	  unpublished	  results	  	  
The	  most	   striking	   finding	  was	   the	  highly	   specific	   expression	  of	   three	   clustered	  miRNAs	  
(miR-­‐99b,	   let-­‐7e,	   and	  miR-­‐125a-­‐5p)	  mapping	   to	   19q13.33	   in	   the	   t(4;14)	   cases.	   It	   has	   very	  
recently	   been	   demonstrated	   that	   these	   miRNAs	   are	   particularly	   abundant	   in	  
hematopoietic	   stem	   cells	   (HSCs),	   and	   that	   miR-­‐125a	   mediates	   HSC	   expansion	   when	  
expressed	   in	   primary	   cells.	   MiR-­‐99a,	   let-­‐7c	   and	   miR-­‐125b,	   which	   are	   moderately	   over-­‐
expressed	   in	   the	   TC5	   cases,	   belong	   to	   a	   paralogous	   cluster	   at	   21q21.1,	   and	   it	   has	   been	  
Figure	   6.	   Identification	   of	   miRNA	   signatures	  
characterizing	   TC	   classes	   (Lionetti	   et	   al.,	  
2009b).	   Heatmap	   of	   the	   differentially	  
expressed	   miRNAs	   in	   MM	   patients	   stratified	  
into	  the	  5	  TC	  groups.	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reported	   that	   miR-­‐125b	   promotes	   B	   lymphocyte	   diversification	   in	   germinal	   centers	   by	  
inhibiting	   the	   premature	   use	   of	   essential	   transcription	   factors	   for	   PC	   differentiation,84	  
thus	   suggesting	   a	   pathogenetic	   role	   for	  miR-­‐125b	   associated	  with	   impaired	   expression.	  
Interestingly,	   none	  of	   the	  miRNAs	   significantly	   discriminating	   the	   TC	   groups	   associated	  
with	   IGH	   translocations	   was	   localized	   in	   the	   chromosomal	   regions	   specific	   for	   the	  
corresponding	   cytogenetic	   abnormality,	   which	   suggests	   that	   mechanisms	   other	   than	  
those	   directly	   deregulating	   mRNA	   expression	   in	   translocation	   events	   may	   modulate	  
miRNA	   expression.	   The	   integrative	   analysis	   defining	   a	   network	   of	   putative	   functional	  
miRNA-­‐target	  regulatory	  relations,	  which	  was	  based	  on	  computational	  target	  prediction	  
and	  supported	  by	  miRNA/mRNA	  expression	  data,	  reinforced	  the	  suggestion	  that	  some	  of	  
the	  miRNAs	  differentially	  expressed	  in	  IGH	  translocated	  cases	  may	  play	  important	  roles	  in	  
the	   biology	   of	  MM	   PCs.	   As	   many	   as	   five	   of	   the	   seven	  miRNAs	   associated	   with	   t(4;14)	  
target	   CBFA2T2,	   a	   nuclear	   repressor	   homologous	   to	   ETO	   that	   binds	   to	   the	   AML1-­‐ETO	  
complex	   and	   may	   play	   a	   role	   in	   hematopoietic	   differentiation,85,86	   and	   let-­‐7e	   targets	  
PTPRE,	  a	  positive	  regulator	  of	  osteoclast	  function	  and	  a	  selective	  inhibitor	  of	  IL-­‐6-­‐	  and	  IL-­‐
10-­‐induced	  JAK-­‐STAT	  signalling87,88.	  
Using	   different	   technical	   and	   analytical	   approaches	   to	   a	   similarly	   representative	  
panel	  of	  patients,	  Gutierrez	  et	  al.	   identified	  a	  number	  of	  miRNAs	  that	  were	  differentially	  
expressed	   in	   myeloma	   cells	   from	   t(4;14),	   t(14;16),	   t(11;14),	   RB-­‐deleted	   (as	   a	   single	  
abnormality)	   or	   cytogenetically	   normal	   patients,	   as	   compared	   with	   healthy	   controls.66	  
Only	   two	   (miR-­‐214	   and	  miR-­‐375)	  were	   commonly	   deregulated	   in	   the	  myeloma	   samples	  
regardless	  of	  cytogenetic	  characteristics.	  Confirming	  previous	  data,64	  miR-­‐1	  and	  miR-­‐133a	  
were	  over-­‐expressed	   in	  patients	  with	   the	   t(14;16)	   chromosomal	   translocation,	   a	   finding	  
that	  strengthens	  the	  hypothesis	  of	  a	  link	  between	  the	  deregulation	  of	  MAF	  genes	  and	  the	  
expression	  of	   this	  miRNA	  cluster.	  By	   combining	   the	  miRNA	  and	  mRNA	  expression	  data	  
from	   the	   same	   samples,	   Gutierrez	   et	   al.	   also	   identified	   putative	   target	   genes	   with	  
important	  roles	  in	  cancer	  or	  the	  control	  of	  MM	  cell	  biology,	  such	  as	  CCND2,	  which	  was	  up-­‐
regulated	   in	  MM	  subtypes	   t(4;14),	   t(14;16)	  and	  monosomy	   13,	  and	  has	   target	   sites	   for	  a	  
number	  of	  the	  miRNAs	  that	  are	  significantly	  deregulated	   in	  these	  cytogenetic	  subtypes.	  
This	  suggests	  that	  the	  underexpression	  of	  various	  miRNAs	  found	  in	  many	  MM	  cases	  may	  
be	  responsible	  for	  the	  increased	  CCND2	  expression.	  
Finally,	   two	   recent	   works	   did	   not	   confirm	   extensively	   previous	   data	   concerning	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specific	  patterns	  of	  miRNA	  expression	  associated	  with	  known	  molecular	  characteristics	  in	  
MM	  patients,	  most	  likely	  because	  of	  the	  relatively	  small	  number	  of	  patients,	  or	  subgroup	  
of,	  included	  in	  the	  series	  investigated	  by	  the	  Authors.67,89	  In	  particular,	  clustering	  analysis	  
in	  the	  paper	  by	  Cothals	  et	  al.	  showed	  that	  miRNA	  expression	  classified	  MM	  patients	  into	  
subgroups	  which	  could	  not	  be	  distinguished	  on	  the	  basis	  of	  other	  known	  characteristics,	  
whereas	   Chi	   et	   al.	   described	   miRNA	   transcripts	   which	   may	   be	   deregulated	   in	   the	  
transition	   from	   normal	   to	   MGUS	   or	   MM	   presentation.	   In	   both	   of	   these	   papers	   the	  
Authors	   described	  miRNAs	   associated	   with	   clinical	   outcome,	   although	   in	   the	   paper	   by	  
Corthals	  et	  al.	   the	  associations	  did	  not	  reach	  significance	  after	  multiple	  test	  corrections.	  
Chi	  et	  al.	  found	  that	  the	  expression	  of	  miR-­‐153,	  miR-­‐490,	  miR-­‐455,	  miR-­‐642,	  miR-­‐500,	  miR-­‐
596,	  miR-­‐548d,	  miR-­‐373,	  miR-­‐554	  and	  miR-­‐888	  was	  related	  to	  event-­‐free	  survival.	  
	  
MiRNA	  expression	  in	  the	  prognostic	  stratification	  of	  myeloma.	  
Zhou	  et	  al.	  analyzed	  the	  miRNA	  expression	  profiling	  in	  two	  healthy	  donors	  and	  52	  
newly	  diagnosed	  MM	  patients,	  and	  concluded	  that	  higher	  total	  miRNA	  expression	  levels	  
(calculated	  as	  the	  mean	  expression	  levels	  of	  expressed	  miRNAs)	  might	  be	  associated	  with	  
the	   onset	   of	   MM.90	   Among	   the	   pathological	   samples,	   unlike	   those	   of	   other	   types	   of	  
cancer,91-­‐94	   higher	   total	   miRNA	   expression	   seemed	   to	   be	   associated	   with	   a	   worse	  
outcome	   as	   it	   was	   positively	   associated	   with	   the	   same	   Authors’	   GEP-­‐defined	   high-­‐risk	  
score	  (RS)	  and	  proliferation	  index	  (PI).78	  In	  line	  with	  this,	  the	  RS	  and	  PI	  were	  associated	  
with	  the	  expression	  of	  a	  number	  of	  miRNAs,	  four	  of	  which	  (miR-­‐106a,	  miR-­‐106b,	  miR-­‐	  17-­‐
5p	  and	  miR-­‐20b)	  target	  the	  tumor	  suppressor	  gene	  p21CIP1	  in	  HMCLs.	  The	  putative	  role	  of	  
miRNA	   over-­‐expression	   in	   myeloma	   progression	   was	   suggested	   by	   the	   silencing	   of	  
EIF2C2/AGO2	   and	  DICER1	   in	  HMCLs,	  which	   led	   to	  decreased	   cell	   viability,	   cell	   cycle	   arrest	  
and	  the	  induction	  of	  apoptosis.	  The	  Authors	  also	  found	  that,	  although	  associated	  with	  a	  
bad	  prognosis	  in	  MM,	  AGO2	  expression	  did	  not	  correlate	  with	  total	  miRNA	  expression	  in	  
the	  primary	  tumor	  samples,	  suggesting	  that	  AGO2	  may	  not	  be	  the	  only	  biogenetic	  factor	  
affecting	  the	  global	  expression	  of	  miRNAs	  in	  myeloma	  cells.	  A	  more	  recent	  study	  of	  the	  
expression	   of	   DICER1	   and	   DROSHA	   genes	   in	   patients	   with	   MGUS,	   smoldering	   and	  
symptomatic	  MM	   found	   that	  DICER1	  was	   less	   expressed	   in	   the	   symptomatic	  MM	   cases	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than	   in	   healthy	   donors	   or	   MGUS	   patients;95	   furthermore,	   among	   the	   symptomatic	  
patients,	  median	   progression-­‐free	   survival	  was	   significantly	   longer	   in	   those	  with	   higher	  
DICER1	  expression	  levels.	  As	  recent	  evidence	  suggests	  that	  alterations	  in	  DICER1	  may	  lead	  
to	  altered	  miRNA	  expression	  levels,96	  an	  apparent	  disagreement	  emerged:	  the	  first	  study	  
directly	   correlated	   higher	   total	  miRNA	   expression	  with	   poorer	   outcomes,	   whereas	   the	  
second	  found	  that	  lower	  DICER1	  expression	  levels	  were	  a	  marker	  of	  shorter	  progression-­‐
free	   survival.	   However,	   the	   miRNA	   biogenesis	   should	   be	   considered	   as	   a	   multi-­‐step	  
process	  and	  an	  alteration	   in	  only	  one	  of	   its	  components	   is	  probably	   insufficient	   to	  alter	  
miRNA	  expression	  as	  a	  whole:	  further	  studies	  are	  warranted	  to	  clarify	  the	  contribution	  of	  
each	  of	  the	  components	  involved	  in	  miRNA	  biogenesis,	  and	  elucidate	  how	  other	  genetic	  
or	  epigenetic	  factors	  can	  lead	  to	  the	  selectively	  altered	  expression	  of	  particular	  miRNAs.	  
Another	  very	  recent	  evidence	  links	  the	  miRNA	  processing	  machinery	  to	  MM	  prognosis:	  a	  
single	   nucleotide	   polymorphism	   (SNP)	   in	   exportin-­‐5	   (XPO5),	   rs11077,	   has	   been	   in	   fact	  
associated	   with	   significant	   longer	   PFS	   and	   OS	   in	   MM	   patients	   after	   ASCT:97	   this	   SNP	  
affected	  protein	  translation	  in	  HMCLs,	  perhaps	  through	  the	  introduction	  of	  a	  binding	  site	  
for	   a	   miRNA.	   In	   the	   same	   paper,	   the	   impact	   of	   miRNAs	   on	   MM	   prognosis	   was	   also	  
inferred	   by	   the	   observation	   that	   KRT81	   rs3660	   C/C	   variant	   was	   associated	   with	  
significantly	  longer	  OS:	  this	  polymorphism	  in	  the	  3’UTR	  region	  of	  the	  gene,	  facilitating	  the	  
binding	   of	   some	  miRNAs	   reported	   to	   be	   up-­‐regulated	   in	  MM,	   produced	   a	   reduction	   in	  
protein	  levels	  that	  correlated	  with	  lower	  proliferation	  in	  HMCLs.	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In	  the	  present	  work,	  based	  on	  the	  findings	  of	  microRNA	  deregulation	  in	  abnormal	  
PCs	  and	   the	   raising	  evidence	  of	   their	  association	  with	  outcome,	  we	   test	   the	  hypothesis	  
that	  some	  patterns	  of	  miRNA	  expression	  in	  myeloma	  could	  correlate	  with	  survival,	  aimed	  
at	  providing	  new	  molecular	  biomarkers	  of	  outcome.	  	  	  
To	  this	  aim,	  we	  analyzed	  the	  miRNA	  expression	  profiles	  of	  a	  large,	  prospective	  and	  
representative	  panel	  of	  163	  primary	  tumors	  included	  in	  the	  phase	  3	  multicenter	  factorial	  
design	   Myeloma	   Research	   Council	   (MRC)	   Myeloma	   IX	   clinical	   trial,	   and	   correlated	   the	  
expression	   with	   overall	   and	   progression	   free	   survival.	   Furthermore,	   we	   evaluated	  
whether	  a	  miRNA-­‐based	  classifier	  might	  be	  proficiently	  used	  to	  stratify	  high	  risk	  myeloma	  
patients	   independent	   of	   and	   integrating	   other	   prognostic	   risk	   stratifications	   (based	   on	  
International	  Staging	  System,	  cytogenetics	  and	  gene	  expression).	  
	  Finally,	  we	   took	   advantage	  of	   the	   corresponding	   gene	   expression	   and	  genome-­‐
wide	  profiles	  available	   for	   the	  patients	   included	   in	   the	  dataset	   to	  evaluate	   the	  putative	  
relationships	  with	  the	  transcriptional	  and	  genomic	  milieu.	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Patient	  samples	  	  	  
	  
Bone	  marrow	   aspirates	  were	   obtained	   from	   newly	   diagnosed	  myeloma	   patients	   in	   the	  
MRC	   Myeloma	   IX	   study	   during	   standard	   diagnostic	   procedures	   following	   informed	  
consent.	  The	  study	  was	  approved	  by	  the	  National	  Research	  Ethics	  Service	  (MREC	  02/8/95)	  
and	  registered	  under	   ISRCTN68454111.	  The	  design,	  patient	  evaluation	  and	  end	  points	  of	  
this	  trial	  have	  been	  extensively	  reported	  previously:98	  in	  summary,	  the	  trial	  recruited	  1960	  
patients,	   who	   were	   allocated	   to	   two	   main	   treatment	   pathways	   (intensive	   or	   non-­‐
intensive)	   at	   the	   discretion	   of	   the	   treating	   physician	   taking	   account	   of	   the	   age	   and	  
performance	  status.	  The	  median	   follow-­‐up	  of	   this	   trial	  at	   the	   time	  of	   the	  present	   study	  
(november,	  2011)	  was	  5.9	  years.	  153	  patients	  with	  GEP	  have	  been	  stratified	  according	  to	  
the	  TC	  classification	  described	  previously.73	  
	  
miRNA	  profiling	  	  
Plasma	   cells	  were	   selected	   to	   a	   purity	   of	   >90%	   as	   determined	   by	   both	  microscopy	   and	  
flow	  cytometry,	  from	  bone	  marrow	  aspirate	  samples	  using	  CD138	  magnetic	  bead	  sorting,	  
subsequently	  small	  RNA	  was	  extracted	  and	  enriched	  using	  a	  modified	  protocol	  for	  Qiagen	  
Allprep	  kit	  or	  Trizol	  Invitrogen	  kit.	  miRNA	  expression	  profiling	  was	  then	  carried	  out	  in	  185	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cases	   according	   to	   Affymetrix	   recommended	   protocol.	   Briefly,	   the	   enriched	   small	   RNA	  
was	  processed	  using	  the	  FlashTag	   labeling	  kit,	  which	  uses	  a	  tailing	  reaction	  followed	  by	  
ligation	  of	  the	  biotinylated	  signal	  molecule	  to	  the	  target	  RNA	  sample.	  The	   labelled	  RNA	  
was	  then	  hybridized	  to	  Affymetrix	  GeneChip®	  microRNA	  arrays	  v1.0	  and	  scanned	  using	  a	  
GeneChip®	  scanner	  3000	  7G.	  Expression	  values	   for	  847	  human	  miRNAs	  were	  extracted	  
from	   CEL	   files	   using	   Affymetrix	   miRNA	   QC	   tool	   software	   (RMA	   normalized	   and	   log2-­‐
transformed).	  After	  quality	  control	  using	  R	  package	  affyPLM,	  163	  samples	  were	  included	  
based	  on	  the	  metrics	  resulting	  from	  NUSE	  (Normalized	  Unscaled	  Standard	  Error)	  analysis,	  
namely	   showing	   values	   less	   than	   1.05.	   The	  microarray	  data	  have	  been	  deposited	   in	   the	  
Gene	   Expression	   Omnibus	   (GEO)	   under	   accession	   number	   GSE41276.	   The	   patients	  
included	   in	   the	  miRNA	  expression	  analysis	  were	  representative	  of	  patients	  entered	   into	  
the	  overall	  trial	  (Table	  1).	  
	  
Table	  1.	  Demographic,	  serological	  and	  molecular	  features	  of	  the	  patients	  included	  in	  the	  
miRNA	  expression	  analysis	  compared	  with	  those	  who	  entered	  into	  the	  overall	  trial.	  No	  
significant	  differences	  at	  P	  <0.05	  were	  evidenced.	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Gene	  Expression	  and	  Copy	  Number	  Analysis	  
Gene	  expression	  profiling	   (GEP)	  of	   261	   samples	  were	  generated	  on	  Affymetrix	  HG-­‐U133	  
Plus	  2.0	  arrays,99	  and	  the	  expression	  values	  were	  RMA	  normalized	  and	  log2-­‐transformed.	  
Affymetrix	  GeneChip	  Mapping	  500K	  Array	  sets	  were	  performed	  as	  described	  in	  Dickens	  et	  
al..99	  Briefly,	   loss-­‐of-­‐hetozigosity	   (LOH)	  and	  copy	  number	  data	  were	  extracted	   from	  the	  
raw	   feature	   intensities	   using	   the	   Affymetrix	   GCOS	   software	   (version	   1.4.0).	   The	   tumor	  
copy	  number	  values	  were	   then	   inferred	  against	  normal	  germ-­‐line	  counterpart,	   for	  each	  
sample,	  using	  Affymetrix	  GTYPE	  software	  and	  dChipSNP.100	  
	  Finally,	   153	   of	   GEP	   samples	   and	   72	   genotyping	   samples	   have	   miRNA	   profiling	   data	  
available	   for	   integrative	   analysis.	   The	   associated	   microarray	   datasets	   have	   been	  
deposited	  into	  GEO	  under	  accession	  number	  GSE15695.	  	  
	  
Quantitative	  RT-­‐PCR	  
The	  expression	  of	  miR-­‐886-­‐5p,	  miR-­‐17	  and	  miR-­‐18a	  was	  analyzed	   in	  puriﬁed	  CD138+	  cells	  
by	   means	   of	   real-­‐time	   quantitative	   polymerase	   chain	   reaction	   (Q-­‐RT-­‐PCR)	   using	   the	  
TaqMan®	  microRNA	  assays	  (Applied	  Biosystems,	  Foster	  City,	  CA)	  in	  accordance	  with	  the	  
manufacturer’s	   protocol.	   The	   measurement	   of	   transcript	   expression	   was	   performed	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using	   the	   Applied	   Biosystems	   StepONE	  Real-­‐Time	   PCR	   System.	   All	   of	   the	   RNA	   samples	  
were	   run	   in	   duplicate	   and	  normalized	  on	   the	  basis	   of	   the	   expression	  of	  miR-­‐103.101	   The	  
threshold	  cycle	  (Ct)	  was	  defined	  as	  the	  fractional	  cycle	  number	  at	  which	  the	  fluorescence	  
passes	   the	   fixed	   threshold.	  All	   signals	  with	  Ct≥	   35	  were	  manually	   set	   to	  undetermined.	  
Data	  were	  expressed	  as	  2-­‐ΔCt	  (Applied	  User	  Bulletin	  No.	  2).	  
	  
Statistical	  analysis	  
All	  analyses	  were	  performed	  in	  R	  2.12.2	  and	  Bioconductor	  2.7.	  Multivariate	  Cox	  regression	  
analyses	   were	   conducted	   to	   investigate	   the	   association	   of	   miRNA	   expression	   with	  
progression-­‐free	   (PFS)	   and	   overall	   survival	   (OS),	   where	   the	   expression	   level	   of	   each	  
miRNA	   were	   used	   as	   continuous	   variable	   and	   treatment	   pathways	   (intensive	   or	   non-­‐
intensive)	   as	   covariate.	   miRNAs	   with	   a	   p-­‐value	   less	   than	   0.05	   were	   selected	   as	   being	  
associated	   with	   survival	   irrespective	   of	   treatment	   pathway.	   For	   robustness,	   only	   the	  
miRNAs	   that	   remained	   significant	   after	   being	   corrected	   for	   multiple	   testing	   (Benjamin	  
and	  Hochberg's	  method,	  P	  <	  0.05)	  were	  used	  to	  construct	  an	  outcome	  classifier	  to	  divide	  
patients	  into	  different	  risk	  groups.	  The	  distribution	  of	  OS	  between	  risk	  groups	  of	  patients	  
was	   estimated	   using	   the	   Kaplan-­‐Meier	  method	   (log-­‐rank	   test).	   Internal	   cross-­‐validation	  
was	  performed	  via	  bootstrapping	  on	  the	  final	  prognostic	  model	  (1000	  replications).	  The	  
independence	  of	  the	  risk	  groups	  defined	  by	  miRNA	  expression	  from	  other	  important	  risk	  
predicting	   factors	   was	   tested	   by	   using	   multivariate	   Cox	   regression.	   Performance	   of	  
predictive	  models	  was	   compared	   by	   likelihood-­‐ratio	   test	   (R	   package	   anova.coxph).	   The	  
association	  of	  trend	  between	  the	  ISS/FISH	  risk	  groups	  and	  the	  miRNA-­‐derived	  risk	  groups	  
was	  investigated	  using	  linear	  by	  linear	  association	  test	  (R	  package	  coin).	  
	  
Differentially	   expressed	  miRNAs	   between	   a	   particular	   TC	   subgroup	   of	   interest	   and	   the	  
other	   subgroups	   were	   selected	   using	   significance	   analysis	   of	   microarray	   (SAM)	  
(Bioconductor	  package	  samr),	  with	  a	  1000-­‐permutation	  adjustment	  and	  5%	  false	  discovery	  
rate	  (FDR).	  	  
As	   stated	   above,	   among	   the	   163	   samples	   there	   were	   also	   72	   cases	   with	   SNP-­‐based	  
mapping	  array	  data	  and	   152	   cases	  with	   fluorescence	   in	   situ	  hybridization	   (FISH)	   results.	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Integrative	  analyses	  were	  carried	  out	  to	  explore	  the	  mechanisms	  of	  miRNA	  deregulation.	  
Either	   Wilcoxon	   or	   Kruskal-­‐Wallis	   test	   was	   used	   to	   look	   at	   the	   associations	   between	  
miRNA	  expression	  levels	  and	  corresponding	  copy	  number	  values,	  as	  well	  as	  FISH	  lesions.	  
	  
miRNA	  target	  prediction	  and	  correlation	  with	  gene	  expression	  
In	  order	  to	  be	  identified	  as	  putative	  targets	  of	  a	  particular	  miRNA,	  genes	  have	  to	  fulfil	  the	  
following	   criteria:	   (1)	   the	   targets	   are	   predicted	   by	   at	   least	   3	   of	   the	   11	   programs	   in	  
miRecords,102	   a	   resource	   for	   animal	   miRNA-­‐target	   interactions	   which	   integrate	   the	  
following	   target	   prediction	   tools:	   DIANA-­‐microT,	  MicroInspector,	   miRanda,	  MirTarget2,	  
miTarget,	  NBmiRTar,	  PicTar,	  PITA,	  RNA22,	  RNAhybrid	  and	  TargetScan;	  (2)	  the	  targets	  are	  
statistically	   associated	   with	   OS	   (P	   <	   0.05).	   The	   association	   between	   GEP	   and	   OS	   was	  
tested	   following	   the	  same	  workflow	  as	  described	  above,	   to	  produce	   two	   lists	  of	  genes	  
associated	   with	   shorter	   OS	   (n=1569)	   and	   longer	   OS	   (n=1311)	   respectively;	   and	   (3),	   a	  
significant	  inverse	  Pearson	  correlation	  needs	  to	  be	  identified	  between	  the	  expression	  of	  a	  
miRNA	   and	   its	   targets	   (P	   <	   0.05).	   Correlation	   analyses	   between	   gene	   expression	   and	  
miRNA	  expression	  was	  carried	  out	  among	  the	  153	  patients	  where	  GEP	  was	  available;	  only	  
those	  interactions	  with	  negative	  correlation	  coefficients	  (r)	  were	  selected.	  













Identification	  of	  miRNA	  expression	  profiles	  associated	  with	   the	  prognostic	  groups	  based	  
on	  TC	  classification	  	  
In	   an	   initial	   analysis	   of	   the	   dataset,	   we	   assessed	   the	  miRNA	   expression	   patterns	   in	   TC	  
classification	  groups	  with	  prognostic	  relevance	  (4p16,	  MAF	  and	  11q13	  groups).	  	  In	  the	  153	  
cases	  with	  both	  GEP	  and	  miRNA	  profiling	  data,	   there	  were	  26	  cases	  of	  4p16,	  7	  cases	  of	  
MAF,	  26	  cases	  of	  11q13,	  42	  cases	  of	  D1,	  31	  cases	  of	  D2,	  12	  cases	  of	  D1+D2,	  1	  case	  of	  D3	  and	  8	  
cases	   of	   unknown	   classification;	   subsequently,	   the	   single	   D3	   case	   and	   the	   unclassified	  
cases	   were	   excluded	   from	   further	   analyses.	   We	   performed	   a	   one-­‐to-­‐one	   comparison	  
between	   the	   test	   groups	   with	   the	   other	   major	   subtypes	   using	   SAM	   in	   144	   cases.	   The	  
resulting	   lists	   were	   examined	   for	   intersections	   to	   find	   the	   miRNAs	   consistently	   being	  
upregulated	  (or	  downregulated)	  in	  the	  subgroup	  of	  interest	  (Table	  2).	  	  
The	  144	  samples	  were	  grouped	  into	  4p16,	  11q13,	  MAF	  and	  others	  (comprising	  D1,	  D2	  and	  
D1+D2)	  based	  on	  TC	  classification,	  and	  the	  expression	  characteristics	  of	  the	  4	  subgroups	  
were	  visualized	  using	  a	  heatmap	  (Figure	  7).	  A	  distinct	  upregulation	  of	  the	  miRNA	  cluster	  
99b/let-­‐7e/125a	  on	  19q	  was	  identified	  in	  TC	  4p16	  cases,	  as	  well	  as	  miR-­‐150/miR-­‐155/miR-­‐34a	  
upregulation	  in	  MAF	  subgroup,	  largely	  confirming	  what	  has	  been	  seen	  previously	  by	  us	  in	  
a	  smaller	  series.	   64	   In	  addition,	  upregulation	  of	  miR-­‐1275	  and	  downregulation	  of	  miR-­‐138	  
were	  observed	  in	  11q13	  cases.	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Table	  2.	  The	  specific	  deregulation	  of	  miRNAs	  in	  (A)	  4p16,	  (B)	  MAF	  and	  (C)	  11q13	  subtypes	  
compared	   to	   other	   subtypes	   (SAM,	   FDR	   <	   0.05	   based	   on	   1000	   permutations).	   The	  
reported	   values	   	   represent	   the	   miRNA’s	   fold	   changes	   in	   the	   subgroup	   of	   interest	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Figure	   7.	   MicroRNA	   signatures	   for	   TC	   classification:	   the	   heatmap	   shows	   the	   distinct	  
expression	   characteristics	   of	   the	   favourable	   11q13	   group,	   unfavourable	   4p16	   and	   MAF	  
groups	   in	  contrast	   to	   the	  rest	  of	  cases	   (D1,	  D2,	  D1+D2),	  according	  to	  the	  8	  differentially	  
expressed	  miRNAs.	   The	   TC	   subgroups	   and	   FISH	   abnormalities	   (green,	   no	   chromosomal	  
abnormality;	   red,	   chromosomal	   abnormality;	   grey,	   not	   known)	   are	   shown	   in	   colours	  
above	  the	  heatmap.	  The	  colour	  scale	  bar	   in	  the	  heatmap	  represents	  the	  relative	  miRNA	  
expression	  with	  red	  representing	  upregulation	  and	  blue	  representing	  downregulation.	  
	  
	  
miRNA	  expression	  associated	  with	  OS	  
After	   removal	   of	   those	   miRNAs	   with	   a	   percentage	   detection	   call	   (defined	   by	  
Affymetrix	   QC	   Tool)	   of	   less	   than	   2%	   across	   the	   samples,	   the	   expression	   values	   of	   38	  
miRNAs	  were	  identified	  as	  being	  associated	  with	  OS	  as	  continuous	  variables	  according	  to	  
Cox	   regression	   analyses	   (P	   <	   0.05,	   Table	   3).	   Three	   clusters	   of	   miRNAs	   located	   at	  
cytobands	  13q31.1	  (mir-­‐17~92:	  miR-­‐17,	  miR-­‐18a,	  miR-­‐20a,	  miR-­‐19b-­‐1,	  miR-­‐92a-­‐1),	  Xq26.2	  (mir-­‐
106a~363:	  miR-­‐106a,	  miR-­‐18b,	  miR-­‐20b,	  miR-­‐19b-­‐2,	  miR-­‐92a-­‐2)	   and	  Xq26.3	   (miR-­‐503,	  miR-­‐
542-­‐5p,	  miR-­‐424-­‐star)	  were	   identified	  as	  being	  associated	  with	  survival,	  comprising	  13	  of	  
the	   38	   potentially	   deregulated	   miRNAs.	   Clusters	   mir-­‐17~92	   and	   mir-­‐106a~363	   are	   of	  
particular	   interest,	   as	   the	   association	   between	   members	   of	   these	   clusters	   and	   OS	  
remained	  significant	  or	  borderline	  significant	  (P	  <	  0.06)	  after	  being	  corrected	  by	  multiple	  
testing	  (Benjamin	  and	  Hochberg's	  method).	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Table	  3.	  miRNAs associated with OS (P < 0.05) (N=38). 24 of them were upregulated 
in shorter survivors (HR > 1.0) and 14 were downregulated (HR < 1.0). Those 
labelled * remained significant after correction for multiple testing. 
	  
miRNAs	   P	  value	   P	  value	  after	  	  
multiple	  testing	  correction	  
Hazard	  Ratio	  (HR)	   Cytoband	  
*	  hsa-­‐miR-­‐886-­‐5p	   .0002	   .0385	   1.74	   5q31.1	  
*	  hsa-­‐miR-­‐18a	   .0002	   .0385	   1.39	   13q31.1	  
*	  hsa-­‐miR-­‐17	   .0003	   .0385	   1.54	   13q31.1	  
hsa-­‐miR-­‐501-­‐3p	   .0005	   .0506	   2.21	   Xp11.23	  
hsa-­‐miR-­‐1260	   .0006	   .0506	   0.31	   14q24.3	  
hsa-­‐miR-­‐18b	   .0007	   .0506	   2.24	   Xq26.2	  
hsa-­‐miR-­‐106a	   .0008	   .0527	   1.52	   Xq26.2	  
hsa-­‐miR-­‐17-­‐star	   .0031	   .1762	   1.45	   13q31.1	  
hsa-­‐miR-­‐339-­‐3p	   .0048	   .2090	   0.75	   7p22.3	  
hsa-­‐miR-­‐503	   .0050	   .2090	   1.57	   Xq26.3	  
hsa-­‐miR-­‐92a	   .0056	   .2090	   1.28	   13q31.1/Xq26.2	  
hsa-­‐miR-­‐20a	   .0056	   .2090	   1.35	   13q31.1	  
hsa-­‐miR-­‐20b	   .0061	   .2115	   1.38	   Xq26.2	  
hsa-­‐miR-­‐129-­‐3p	   .0111	   .3477	   2.49	   7q32.1/11p11.2	  
hsa-­‐miR-­‐19b	   .0116	   .3477	   1.30	   13q31.1/Xq26.2	  
hsa-­‐miR-­‐494	   .0124	   .3482	   1.64	   14q32.31	  
hsa-­‐miR-­‐575	   .0137	   .3617	   1.43	   4q21.22	  
hsa-­‐miR-­‐615-­‐3p	   .0153	   .3833	   0.40	   12q13.13	  
hsa-­‐miR-­‐31	   .0179	   .4156	   1.78	   9p21.3	  
hsa-­‐miR-­‐1308	   .0188	   .4156	   1.20	   p22.11	  
hsa-­‐miR-­‐629	   .0201	   .4156	   1.62	   15q23	  
hsa-­‐miR-­‐542-­‐5p	   .0203	   .4156	   2.32	   Xq26.3	  
hsa-­‐miR-­‐424-­‐star	   .0217	   .4239	   1.60	   Xq26.3	  
hsa-­‐miR-­‐891b	   .0247	   .4627	   0.43	   Xq27.3	  
hsa-­‐miR-­‐152	   .0258	   .4651	   0.85	   17q21.32	  
hsa-­‐miR-­‐155	   .0300	   .5108	   0.91	   21q21.3	  
hsa-­‐miR-­‐890	   .0306	   .5108	   1.65	   Xq27.3	  
hsa-­‐miR-­‐1271	   .0353	   .5387	   2.07	   5q35	  
hsa-­‐miR-­‐650	   .0361	   .5387	   1.21	   22q11.22	  
hsa-­‐miR-­‐886-­‐3p	   .0374	   .5387	   1.28	   5q31.1	  
hsa-­‐miR-­‐16-­‐1-­‐star	   .0376	   .5387	   0.40	   13q14.2	  
hsa-­‐miR-­‐541	   .0383	   .5387	   0.49	   14q32.31	  
hsa-­‐miR-­‐1324	   .0418	   .5698	   0.49	   3p12.3	  
hsa-­‐let-­‐7g-­‐star	   .0449	   .5757	   0.54	   3p21.1	  
hsa-­‐miR-­‐491-­‐5p	   .0455	   .5757	   0.63	   9p21.3	  
hsa-­‐miR-­‐216b	   .0468	   .5757	   0.54	   2p16.1	  
hsa-­‐miR-­‐92a-­‐2-­‐star	   .0481	   .5757	   0.56	   Xq26.2	  
hsa-­‐miR-­‐570	   .0486	   .5757	   0.67	   3q29	  
	  
	  
Some	   miRNAs	   located	   within	   these	   two	   clusters	   are	   homologous	   in	   sequence	   and,	  
therefore,	   are	   classified	   as	  members	   of	   the	   same	   family	   (Figure	   8).	   The	  miRNAs	  within	  
these	   clusters	   were	   co-­‐expressed	   in	   our	   data,	   suggesting	   that	   they	   are	   subject	   to	  
common	   regulatory	   mechanisms.	   An	   exception	   is	   miR-­‐363	   located	   within	   the	   mir-­‐
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106a~363	   cluster,	   which	   might	   be	   due	   to	   the	   presence	   of	   an	   alternative/additional	  
regulatory	  mechanism.	  The	  expression	   levels	  of	  miR-­‐17	  and	  miR-­‐106a,	  despite	  belonging	  
to	  separate	  clusters	   located	  on	  different	  chromosomes,	  are	  highly	  correlated	  (r	  =	  0.94).	  
The	  higher	  expression	  of	  miR-­‐886-­‐5p	  and	  miR-­‐886-­‐3p,	  originating	  from	  opposite	  arms	  of	  
the	  same	  pre-­‐miRNA,	  are	  both	  associated	  with	  shorter	  OS.	  
	  
Figure	  8.	  MIR17HG	  and	  MIR106~363	  clusters	  and	  their	  roles	  in	  myeloma	  pathogenesis:	  the	  
scheme	  depicts	  the	  genomic	  structure	  of	  the	  miRNA	  clusters	  located	  on	  chromosomes	  13	  
and	  X.	  The	  colours	  indicate	  sequence	  homology	  between	  the	  individual	  miRNAs.	  miRNAs	  
labelled	  with	  *	  are	  upregulated	  in	  short	  survivors	  (P	  <	  005).	  
	  
miRNA	  expression	  associated	  with	  PFS	  	  
Using	   the	  same	  work-­‐flow	  as	   for	  OS,	  35	  miRNA	  were	   identified	  being	  associated	  
with	  PFS.	  Although	  after	  correction	  for	  multiple	  testing	  none	  of	  these	  miRNAs	  remained	  
significant,	   it	   is	  worth	  mentioning	  that	  the	  members	  of	  the	  cluster	  at	  19q13	  (let-­‐7e,	  miR-­‐
125a-­‐5p	  and	  miR-­‐99b)	  being	  identified	  strongly	  associated	  with	  TC	  4p16	  were	  among	  the	  
top	  6	  most	  differentially	  expressed	  miRNAs	  associated	  with	  PFS,	  adding	  further	  evidence	  
to	  the	  global	  prognostic	  importance	  of	  the	  t(4;14)	  in	  myeloma	  (Table	  4).	  
	   	  




Table	  4.	  miRNAs	  associated	  with	  PFS	  (unadjusted	  P	  <	  0.05).	  
	  
Construction	  of	  a	  miRNA-­‐based	  classifier	  for	  OS	  
Three	   upregulated	   miRNAs	   (miR-­‐886-­‐5p,	   miR-­‐17	   and	   miR-­‐18a)	   were	   significantly	  
associated	   with	   OS	   after	   correction	   for	   multiple	   testing	   (Benjamin	   and	   Hochberg's	  
method,	  P	  <	  0.05).	  The	  expression	  of	  these	  miRNAs	  was	  validated	  by	  means	  of	  Q-­‐RT-­‐PCR	  
in	  a	   fraction	  of	  samples	   (58	  cases).	  A	  very	  good	  concordance	  with	  microarray	  data	  was	  
found	   for	   all	   transcripts	   (Pearson	   correlation	   coefficients	   of	   the	   expression	   of	   each	  
miRNA	   P	  value	   P	  value	  after	  multiple	  
testing	  correction	  
HR	   Cytoband	  
hsa-­‐miR-­‐339-­‐3p	   0.00017	   0.07534	   0.701153	   7p22.3	  
hsa-­‐miR-­‐99b	   0.001165	   0.220564	   1.461024	   19q13.41	  
hsa-­‐miR-­‐125a-­‐5p	   0.00161	   0.220564	   1.249882	   19q13.41	  
hsa-­‐miR-­‐9-­‐star	   0.001992	   0.220564	   3.360287	   5q14.3/15q26.1/1q22	  
hsa-­‐miR-­‐650	   0.003322	   0.294368	   1.27696	   22q11.22	  
hsa-­‐let-­‐7e	   0.004263	   0.314777	   1.246946	   19q13.41	  
hsa-­‐miR-­‐1285	   0.005716	   0.326173	   2.286495	   2p13.3/7q21-­‐q22	  
hsa-­‐miR-­‐551b-­‐star	   0.00589	   0.326173	   2.934288	   3q26.2	  
hsa-­‐miR-­‐409-­‐3p	   0.00753	   0.367169	   0.409305	   14q32.31	  
hsa-­‐miR-­‐491-­‐5p	   0.008526	   0.367169	   0.578563	   9p21.3	  
hsa-­‐miR-­‐1202	   0.009117	   0.367169	   1.523442	   6q25.3	  
hsa-­‐miR-­‐512-­‐5p	   0.011773	   0.434629	   2.364608	   19q13.42	  
hsa-­‐miR-­‐25-­‐star	   0.01562	   0.480018	   1.642398	   7q22.1	  
hsa-­‐miR-­‐338-­‐3p	   0.016025	   0.480018	   0.493484	   17q25.3	  
hsa-­‐miR-­‐194	   0.016442	   0.480018	   1.406287	   11q13.1/1q41	  
hsa-­‐miR-­‐200c	   0.01788	   0.480018	   1.303194	   12p13.31	  
hsa-­‐miR-­‐548p	   0.018421	   0.480018	   2.79399	   5q21.1	  
hsa-­‐miR-­‐151-­‐3p	   0.023515	   0.564778	   1.856842	   8q24.3	  
hsa-­‐miR-­‐135a-­‐star	   0.024496	   0.564778	   2.357257	   3p21.1/12q23.1	  
hsa-­‐miR-­‐548i	   0.025498	   0.564778	   0.472353	   8p23.1/3q21.2/4p16.1/Xq21.1	  
hsa-­‐miR-­‐339-­‐5p	   0.02788	   0.588126	   0.768534	   7p22.3	  
hsa-­‐miR-­‐626	   0.029375	   0.591516	   0.436553	   15q15.1	  
hsa-­‐miR-­‐664	   0.033687	   0.599703	   0.458207	   1q41	  
hsa-­‐let-­‐7a-­‐star	   0.033988	   0.599703	   0.476679	   9q22.32/22q13.31/11q24.1	  
hsa-­‐miR-­‐1295	   0.034652	   0.599703	   2.315558	   1q24.3	  
hsa-­‐miR-­‐150-­‐star	   0.036524	   0.599703	   1.45902	   19q13.33	  
hsa-­‐miR-­‐744	   0.038362	   0.599703	   1.299559	   17p12	  
hsa-­‐miR-­‐503	   0.039966	   0.599703	   1.33183	   Xq26.3	  
hsa-­‐miR-­‐139-­‐5p	   0.040541	   0.599703	   1.88743	   11q13.4	  
hsa-­‐miR-­‐483-­‐5p	   0.040612	   0.599703	   1.7496	   11p15.5	  
hsa-­‐miR-­‐125b	   0.044886	   0.618771	   1.108454	   21q21.1/11q24.1	  
hsa-­‐miR-­‐16-­‐1-­‐star	   0.04525	   0.618771	   0.453842	   13q14.2	  
hsa-­‐miR-­‐589	   0.047881	   0.618771	   0.53818	   7p22.1	  
hsa-­‐miR-­‐606	   0.048302	   0.618771	   0.619731	   10q22.2	  
hsa-­‐miR-­‐18b-­‐star	   0.048887	   0.618771	   1.918677	   Xq26.2	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miRNA	  as	  determined	  by	  microarray	  or	  Q-­‐RT-­‐PCR	  were	  0.86,	  0.72	  and	  0.75	  respectively).	  
Unsupervised	   K-­‐means	   clustering	   was	   applied	   to	   each	   miRNA	   across	   163	   samples	   to	  
define	   a	   threshold	   splitting	   samples	   with	   higher	   expression	   from	   those	   with	   lower	  
expression	  (Figure	  9).	  	  
	  
	  
Figure	   9.	  Density	   plots	   showing	   expression	   pattern	   of	  miR-­‐17,	  miR-­‐18a	   and	  miR-­‐886-­‐5p	  
across	  163	  samples	  and	  the	  thresholds	  for	  high	  and	  low	  expression.	  
	  
	  
After	  stepwise	  selection	  in	  a	  multivariate	  Cox	  regression	  model,	  using	  treatment	  pathway	  
as	  a	  covariate,	  miR-­‐886-­‐5p	  and	  miR-­‐17	  were	  shown	  to	  have	  the	  strongest	  discriminative	  
power	   for	   OS	   (Figure	   10);	   consequently	   these	   two	  miRNAs	  were	   used	   to	   construct	   an	  
outcome	  classifier.	  	  
	  
	  
Figure	   10.	  Kaplan-­‐Meier	  estimated	  curves	  of	   the	  groups	  defined	  by	  high/low	  expression	  
levels	  of	  miR-­‐886-­‐5p	  (left	  panel)	  and	  miR-­‐17	  (right	  panel),	  which	  is	  consistent	  across	  both	  
treatment	  pathways.	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The	  proportion	  of	  samples	  defined	  as	  having	  higher	  expression	  of	  miR-­‐886-­‐5p	  and	  miR-­‐17	  
were	  24.5%	  and	  56.4%	  respectively.	  Based	  on	  the	  expression	  levels	  of	  these	  two	  miRNAs,	  
163	   patients	  were	   divided	   into	   three	   groups:	   a	   high	   risk	   group	   (both	   expression	   levels	  
high)	  comprising	  13.5%	  of	  the	  patients,	  a	  median	  risk	  group	  (either	  high)	  comprising	  54%	  
cases	  and	  a	   low	   risk	  group	   (both	   low)	   comprising	  32.5%	   cases	   (Figure	   11A).	   These	   three	  
groups	  have	  significantly	  differential	  OS	  (log-­‐rank	  test	  P	  =	  0.001,	  median	  OS	  19.4	  months	  
vs.	   40.6	   months	   vs.	   65.3	   months).	   The	   median	   risk	   group	   and	   high	   risk	   group	   have	   a	  
hazard	  ratio	   (HR)	  of	   1.79	  (95%	  Confidence	   Intervals	   [CI]:	   1.15-­‐2.78)	  and	  2.89	  (95%	  CI	   1.60-­‐
5.20),	   respectively,	   relative	   to	   the	   low	   risk	   group.	   The	   stability	   of	   the	   miRNA-­‐based	  
classifier	  was	  assessed	  using	  bootstrap	  resampling.	  Based	  on	  1000	  replicates,	   the	  mean	  
significance	  was	  0.004	  with	  a	   standard	  error	  of	  0.02,	   and	   the	  majority	   (98.4%)	  of	   the	  P	  
values	   were	   less	   than	   0.05.	   It	   is	   not	   surprising	   that	   the	   OS	   classifier	   based	   on	   the	  
expression	  of	  two	  miRNAs	  was	  not	  associated	  with	  PFS	  in	  this	  dataset,	  since	  neither	  miR-­‐
17	  nor	  miR-­‐886-­‐5p	  expression	  was	  associated	  with	  PFS;	  although	  the	  pathogenic	  role	  of	  
mir-­‐17~92	  in	  myeloma	  has	  been	  well	  demonstrated.51,103	  To	  exclude	  the	  possibility	  that	  the	  
association	   of	  miRNA	   classifier	   with	   OS	  was	   due	   to	   non-­‐myeloma-­‐related	  mortality,	   22	  
cases	   who	   died	   from	   reasons	   other	   than	   progressive	   myeloma	   (mostly	   other	   cancers,	  
heart	   disease,	   stroke	   and	   infection)	   were	   censored	   at	   the	   time	   of	   death.	   The	   results	  
showed	   that	   the	   three	   risk	  groups	   still	   had	   significantly	  differential	   effect	  on	  myeloma-­‐
specific	  survival	  (log-­‐rank	  test	  P	  =	  0.002,	  median	  survival	  28.2	  months	  vs.	  51.5	  months	  vs.	  
not	  reached).	  Further	  analysis	  on	  post-­‐relapse	  survival	  for	  141	  cases	  who	  relapsed	  before	  
or	  at	  the	  time	  of	  death	  showed	  a	  strikingly	  differential	  effect	  among	  the	  three	  risk	  groups	  
(log-­‐rank	   test	  P	   =	   2.4x10-­‐7,	  median	   survival	   6.1	  months	   vs.	   18.1	  months	   vs.	   35.1	  months,	  
Figure	  11B),	  which	  largely	  accounted	  for	  its	  impact	  on	  OS	  while	  lacking	  the	  significance	  on	  
PFS.	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Figure	  11.	  Survival	  of	  patients	  was	  stratified	  according	  to	  the	  miRNA-­‐based	  classifier.	  (A)	  
Patients	   (N	   =	   163)	   were	   divided	   into	   three	   groups:	   high	   risk	   (both	   miRNA	   expression	  
high),	  median	  risk	  (either	  high)	  and	  low	  risk	  (both	  low)	  based	  on	  expression	  levels	  of	  miR-­‐
17	   and	  miR-­‐886-­‐5p.	   (B)	   Further	   analysis	   on	   post-­‐relapse	   survival	   for	   141	   relapsed	   cases	  
showed	   a	   remarkable	   differential	   effect	   among	   the	   three	   risk	   groups.	   (C)	   The	  miRNA-­‐
based	   classifier	   is	   also	   able	   to	   identify	   subgroups	   within	   22	   t(4;14)	   cases,	   which	   had	  
differential	   OS	   (median	   13.8,	   25.3	   and	   71.0	   months	   respectively,	   P	   =	   0.005).	   (D)	   In	   45	  
patients	   classified	   as	   being	   at	   low	   risk	   by	   ISS	   plus	   FISH	   abnormalities	   those	   with	   high	  
expression	  of	  at	   least	  one	  of	  the	  two	  miRNAs	  (miR-­‐17	  and	  miR-­‐886-­‐5p)	  have	  shorter	  OS	  
compared	  to	  the	  rest	  of	  the	  cases	  (median	  47.6	  months	  vs	  not	  reached,	  P	  =	  0.01).	  
	  
	  
The	   miRNA-­‐based	   classifier	   improves	   the	   ISS/FISH	   based	   risk	   stratification	   and	   is	  
independent	  of	  GEP	  signatures	  
International	   Staging	   System	   (ISS)	   and	   FISH	   abnormalities	   including	   adverse	   IgH	  
translocations	   [t(4;14),	   t(14;16)	   or	   t(14;20)],	   gain(1q)	   and	   del(17p)	   have	   been	   previously	  
identified	  as	  independent	  prognostic	  factors,104	  as	  was	  the	  treatment	  pathway	  (log-­‐rank	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test	  P	   <	   0.001)	   in	   the	  MRC	  Myeloma	   IX	   dataset	   examined	  here.	   Therefore,	  multivariate	  
Cox	  regression	  analysis	  was	  carried	  out	  to	  test	  the	  independence	  of	  the	  miRNA-­‐based	  risk	  
groups	  from	  these	  important	  predictive	  factors.	  The	  results	  of	  this	  analysis	  confirmed	  the	  
independent	   prognostic	   value	  of	   the	  miRNA-­‐based	   classifier	   (P	   =	   0.0004,	   Table	   5).	   This	  
model	  shows	  a	  significant	  improvement	  of	  predictive	  capability	  compared	  to	  that	  without	  
the	   miRNA-­‐based	   classifier	   (likelihood-­‐ratio	   test	   P	   =	   0.0004).	   Furthermore	   the	   miRNA-­‐
based	  classifier	  is	  able	  to	  identify	  subgroups	  within	  t(4;14)	  cases	  with	  different	  outcome	  
(median	  OS	  13.8,	  25.3	  and	  71.0	  months	  respectively,	  P	  =	  0.005)	  (Figure	  11C),	  while	  no	  other	  
FISH	  lesions	  could	  identify	  prognostically	  significant	  subgroups	  within	  these	  t(4;14)	  cases	  
(p	  >	  0.05,	  data	  not	  shown).	  
	  
Table	   5.	  Multivariate	  Cox	   regression	   analysis	   showing	   the	   independence	  of	   the	  miRNA-­‐
defined	   risk	   groups	   from	   other	   important	   predictive	   factors	   in	   97	   patients	   with	   all	  
variables	  available.	  
 HR HR-95%CI P-value  
miR-groups 2.11 1.40-3.20 0.0004 *** 
ISS 1.37 0.97 -1.95 0.08  
Adverse_translocations 2.25 1.18 -4.28 0.01 * 
Gain(1q) 0.98 0.57-1.68 0.94  
Del(17p) 3.14 1.16 -8.52 0.02 * 
Path (non-intensive) 2.67 1.53-4.64 0.0005 *** 
***	  P	  <	  0.001;	  	  **	  P	  <	  0.01;	  	  *	  P	  <	  0.05	  
	  
	  
Recently,	   a	   prognostic	   model	   has	   been	   developed	   by	   us	   based	   on	   the	   co-­‐
segregation	  of	  adverse	  prognostic	  FISH	  lesions	  and	  the	  ISS.104	  	  We	  investigated	  whether	  
the	   miRNA	   classifier	   could	   be	   usefully	   incorporated	   into	   this	   type	   of	   risk	   stratification	  
approach.	  We	  found	  a	  positive	  association	  between	  the	  ISS/FISH	  risk	  groups	  and	  the	  risk	  
groups	  defined	  by	  the	  miRNA-­‐based	  classifier	  (linear	  by	  linear	  association	  test	  P	  =	  0.005)	  
(Table	   6).	   Importantly,	   despite	   this	   association,	   the	   ISS/FISH	   low-­‐risk	   patients	   who	  
showed	   high	   expression	   levels	   of	   at	   least	   one	   of	   these	   two	   miRNAs,	   had	   shorter	   OS	  
(median	  47.6	  months)	  compared	  to	  the	  remaining	  patients,	  70%	  of	  whom	  remained	  alive	  
after	  7	  years	  (P	  =	  0.01)	  (Figure	  11D).	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Table	  6.	  Matrix	  depicting	  a	  positive	  correlation	  between	   the	   risk	  groups	  based	  on	  FISH	  
abnormalities	  &	  ISS	  and	  the	  risk	  groups	  defined	  by	  miRNA-­‐based	  classifier	  (linear	  by	  linear	  
association	  test	  P	  =	  0.005).	  
	  
 Risk groups defined by miRNA-based classifier 
Risk groups based on FISH 
abnormalities and ISS 
Low (%) Median (%) High (%) Grand Total (%) 
Low 20 (44.4) 19 (42.2) 6 (13.3) 45 (100) 
Intermediate 10 (27.8) 22 (61.1) 4 (11.1) 36 (100) 
High 0 12 (75) 4 (25) 16 (100) 
Grand Total 30 53 14 97 
	  
The	  expression	   levels	  of	   some	   individual	  miRNAs	  belonging	   to	   the	  mir-­‐17~92	  and	  
mir-­‐106a~363	  clusters	  have	  previously	  been	  reported	  as	  being	  associated	  with	  the	  UAMS’	  
GEP-­‐defined	   risk	   score.90	   By	   using	   the	   published	   method78	   we	   applied	   this	   70-­‐gene	  
signature	  to	  our	  series	  of	  153	  samples	  with	  matching	  GEP	  data	  to	  stratify	  them	  into	  high-­‐	  
and	   low-­‐risk	  groups	  based	  on	  the	  gene-­‐risk	  model.	  Then,	  we	  constructed	  a	  multivariate	  
model	   including	   both	   70-­‐gene-­‐defined	   risk	   groups	   and	   miRNA-­‐defined	   risk	   groups,	  
showing	  that	  miRNA-­‐based	  classifier	   retained	   independent	  prognostic	  significance	   from	  
UAMS’	   gene-­‐risk	  model	   (P	   =	   0.002).	   In	   a	   similar	   fashion,	   the	   prognostic	   value	   of	   the	   2-­‐
miRNA	   model	   was	   also	   confirmed	   to	   be	   independent	   from	   both	   IFM-­‐signature105	   and	  
Myeloma	  IX	  6-­‐gene	  signature99	  with	  even	  more	  significant	  effect	  (P	  <	  0.001).	  	  
	  
Putative	  targets	  of	  OS-­‐associated	  miRNAs	  	  
Since	  miRNAs	  have	  been	  shown	  to	  exert	  the	  functional	  effects	  via	  cleavage	  of	  the	  
mRNAs	  of	  their	  target	  genes,106,107	  we	  looked	  at	  the	  putative	  targets	  of	  the	  OS-­‐associated	  
miRNAs	   to	   gain	   insights	   into	   potential	   mechanistic	   associations.	   In	   this	   context	   it	   is	  
known	   that	   the	   members	   of	   mir-­‐17~92	   and	   mir-­‐106a~363	   clusters	   share	   sequence	  
homology	   and	   therefore	   could	   potentially	   target	   the	   same	   genes.	   Validated	   targets	   of	  
these	  miRNAs	  include	  CDKN1A,	  SOCS1	  and	  BCL2L11	  in	  myeloma	  cell	  lines,51,90	  together	  with	  
the	  pro-­‐apoptotic	  genes	  PTEN,	  E2F1	   and	   the	   anti-­‐angiogenic	  genes	  CTGF,	  THBS1	   in	  other	  
cell	   types.108-­‐111	   We	   assessed	   the	   correlation	   of	   expression	   of	   these	   miRNAs	   with	   their	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potential	  target	  genes	  (PTEN,	  E2F1,	  CTGF	  and	  THBS1)	  in	  153	  patient	  samples	  for	  whom	  both	  
miRNA	  and	  gene	  expression	  profiling	  data	  were	  available.	  The	  results	  showed	  that	  there	  
were	   significant	   inverse	   correlations	   between	   E2F1	   expression	   and	   at	   least	   one	   of	   the	  
cluster	  members	  (P	  <	  0.05).	  Trends	  have	  also	  been	  observed	  for	  the	  expression	  levels	  of	  
CTGF,	  THBS1	  and	  PTEN	  being	  inversely	  correlated	  with	  members	  of	  these	  two	  clusters.	  This	  
observation	   suggests	   that	   the	   expression	   levels	   of	   these	   genes	   may	   be	   pathologically	  
relevant	  to	  the	  adverse	  prognosis	  associated	  with	  the	  expression	  of	  these	  miRNAs.	  Using	  
the	  selection	  criteria	  described	  in	  the	  methods	  section,	  the	  putative	  targets	  of	  miR-­‐886-­‐
5p,	  the	  other	  miRNA	  forming	  the	  classifier,	  were	  identified	  (Table	  7).	  Among	  these,	  lower	  
expression	  of	   the	  top	  candidate	  target	  NR3C1	  was	  associated	  with	  shorter	  OS	  (data	  not	  
shown).	  
	  
Table	  7.	  Putative	  targets	  of	  miR-­‐886-­‐5p	  identified	  using	  the	  selection	  criteria	  described	  in	  
methods	  (ranked	  by	  p	  values	  for	  correlation	  between	  miRNA	  and	  mRNA	  expression).	  	  








P	  Value	  for	  
Correlation	  
NR3C1	  
nuclear	  receptor	  subfamily	  3,	  group	  C,	  member	  1	  
(glucocorticoid	  receptor)	  
chr5q31.3	   3	   0.0017	  
TEX261	   testis	  expressed	  261	   chr2p13.3	   3	   0.0049	  
LDLR	   low	  density	  lipoprotein	  receptor	   chr19p13.3	   3	   0.0054	  
MXRA7	   matrix-­‐remodelling	  associated	  7	   chr17q25.1	   3	   0.0107	  
RAB11FIP4	   RAB11	  family	  interacting	  protein	  4	  (class	  II)	   chr17q11.2	   3	   0.0115	  
IQSEC1	   IQ	  motif	  and	  Sec7	  domain	  1	   chr3p25.2	   3	   0.0134	  
SH2B1	   SH2B	  adaptor	  protein	  1	   chr16p11.2	   3	   0.0156	  
PLA2G2D	   phospholipase	  A2,	  group	  IID	   chr1p36.12	   3	   0.0164	  
MED22	   mediator	  complex	  subunit	  22	   chr9q34.2	   3	   0.0175	  
CLN6	   ceroid-­‐lipofuscinosis,	  neuronal	  6,	  late	  infantile,	  variant	   chr15q23	   3	   0.0190	  
FADS2	   fatty	  acid	  desaturase	  2	   chr11q12.2	   3	   0.0213	  
PLEKHA1	  
pleckstrin	  homology	  domain	  containing,	  family	  A	  
(phosphoinositide	  binding	  specific)	  member	  1	  
chr10q26.13	   3	   0.0276	  
ICOSLG	   inducible	  T-­‐cell	  co-­‐stimulator	  ligand	   chr21q22.3	   3	   0.0329	  
GNG7	   guanine	  nucleotide	  binding	  protein	  (G	  protein),	  gamma	  7	   chr19p13.3	   3	   0.0369	  
FAM109A	   family	  with	  sequence	  similarity	  109,	  member	  A	   chr12q24.12	   3	   0.0478	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The	  correlation	  of	  OS-­‐associated	  miRNAs	  with	  cytogenetic	  abnormalities,	  copy	  numbers	  
and	  transcriptional	  regulation	  
We	   examined	   the	   association	   between	  miR-­‐17	   and	  miR-­‐886-­‐5p	   expression	   levels	  
and	   FISH	   abnormalities	   including	   del(13q),	   del(17p),	   t(4;14),	   del(1p)	   and	   gain(1q).	   The	  
results	  of	   this	   analysis	   showed	   that	  miR-­‐17	   expression	  was	   significantly	   associated	  with	  
del(1p)	   and	   gain(1q)	   (P	   <	   0.05).	   However,	   although	   miR-­‐17	   is	   located	   on	   13q,	   which	   is	  
frequently	   deleted	   in	   myeloma	   patients,	   we	   did	   not	   find	   any	   correlation	   between	   13q	  
deletion	   and	   the	   expression	   level	   of	   this	   miRNA.	   The	   expression	   of	   miR-­‐886-­‐5p	   was	  
associated	   with	   t(4;14)	   and	   del(13q)	   (P	   <	   0.05).	   This	   is	   not	   surprising	   as	   these	  
abnormalities	  are	  very	  tightly	  linked.	  	  In	  order	  to	  explore	  further	  how	  these	  two	  miRNAs	  
are	   deregulated	   in	  myeloma,	  we	   investigated	   the	   correlation	  between	   their	   expression	  
and	   the	   tumour	  acquired	  DNA-­‐based	  copy	  number	  at	   their	   chromosomal	   locations.	  Our	  
data	   indicated	   that	  neither	  miR-­‐17	  nor	  miR-­‐886-­‐5p	  expression	   levels	  were	   copy	  number	  
sensitive	  (Figure	  12),	  suggesting	  that	  other	  mechanisms	  could	  be	  responsible.	  	  
Finally,	  as	  the	  mir-­‐17~92	  and	  mir-­‐106a~363	  clusters	  have	  previously	  been	  shown	  to	  
be	  activated	  by	  Myc	  and	  E2F3	  (O'Donnell	  et	  al.,	  2005;	  Woods	  et	  al.,	  2007),	  we	  evaluated	  
the	  correlations	  between	  the	  gene	  expression	  and	  the	  expression	  of	  the	  miRNAs	  within	  
these	  two	  clusters,	  and	  significant	  positive	  correlations	  were	  identified	  for	  both	  genes	  (P	  
<	  0.05).	  	  
	  
	  
Figure	   12.	  The	  correlation	  analyses	  of	  miRNA	  expression	  and	  their	  copy	  numbers	   show	  
that	  the	  expression	  levels	  of	  miR-­‐886-­‐5p	  and	  miR-­‐17	  are	  not	  copy	  number	  sensitive.	  















In	   the	   present	   study,	  we	   have	   comprehensively	   analyzed	   the	  miRNA	   expression	  
profiling	   in	   a	   prospective	   cohort	   including	   163	   cases	   from	   Myeloma	   IX	   l	   trial,	   and	  
correlated	  the	  miRNAs	  expression	  pattern	  with	  outcome	  in	  order	  to	  outline	  their	  possible	  
role	   in	  MM	  prognostication.	   In	  myeloma,	   the	   TC	   classification	   has	   been	   used	   to	   define	  
subgroups	   with	   distinct	   prognoses	   with	   the	   11q13	   translocated	   group	   being	   linked	   to	  
favourable	  outcome	  and	  4p16	  and	  MAF	  translocated	  groups	  being	  linked	  to	  unfavourable	  
outcome.	  In	  our	  study,	  8	  miRNAs	  were	  identified	  as	  being	  deregulated	  distinctly	  in	  these	  
three	   subgroups,	   suggesting	   that	   these	   miRNAs	   could	   play	   an	   important	   role	   in	   the	  
pathogenesis	  of	  these	  distinct	  molecular	  subgroups.	  
Among	   the	   differentially	   expressed	   miRNAs,	   miR-­‐125a,	   let-­‐7e,	   miR-­‐150,	   miR-­‐34a	  
(positively	   associated	   with	   either	   TC	   4p16	   or	  MAF)	   and	  miR-­‐138	   (negatively	   associated	  
with	  TC	  11q13)	  have	  also	  been	  shown	  to	  be	  upregulated	  in	  myeloma	  cells	  in	  comparison	  to	  
their	  normal	  counterparts.51,67,90	  The	  cluster	  of	  miRNAs	  that	  was	  strongly	  correlated	  with	  
TC	  4p16,	  including	  miR-­‐125a,	  let-­‐7e	  and	  miR-­‐99b,	  was	  shown	  to	  be	  associated	  with	  shorter	  
PFS	   in	   our	   dataset.	   Interestingly	   miR-­‐125a	   has	   been	   demonstrated	   to	   have	   a	   role	   in	  
hematopoietic	   stem	   cells,	   increasing	   their	   number	   both	   in	   vivo	   and	   in	   vitro,112,113	  
suggesting	  possible	  relevance	  to	  myeloma	  stem	  cell	  biology.	  In	  addition,	  transgenic	  mice	  
ectopically	   expressing	   the	   MAF-­‐associated	   miRNAs	   (miR-­‐150	   or	   miR-­‐155)	   either	   show	  
dramatic	  impairment	  of	  B	  cell	  differentiation114	  or	  develop	  high-­‐grade	  B	  cell	  lymphoma.115	  	  
CCND1	  has	  been	  previously	  identified	  as	  direct	  target	  of	  miR-­‐138,116	  which	  was	  significantly	  
downregulated	  in	  TC	  11q13.	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We	   found	   three	   clusters	   of	   miRNAs	   associated	   with	   adverse	   OS	   outcome	   in	  
myeloma	  patients:	  mir-­‐503~424	  (on	  Xq26.3),	  mir-­‐17~92	  (on	  13q31.1)	  and	  mir-­‐106a~363	  (on	  
Xq26.2).	   The	   expression	   level	   of	   mir-­‐503~424	   has	   previously	   been	   found	   to	   be	  
upregulated	   in	   malignant	   tissues	   and	   has	   been	   associated	   with	   impaired	   survival	   in	   a	  
number	  of	  cancers,117-­‐119	  supporting	   its	  potential	  relevance.	  Previous	  studies	  have	  shown	  
that	  members	  of	  the	  clusters	  mir-­‐17~92	  and	  mir-­‐106a~363	  are	  downregulated	  during	  the	  
normal	  germinal	  center	  B-­‐cell	  to	  plasma	  cell	  transition,120	  suggesting	  that	  upregulation	  of	  
these	   variants	   in	   plasma	   cells	   may	   adversely	   affect	   their	   biological	   behaviour.	   Indeed,	  
previous	   work	   on	   miRNA	   expression	   in	   myeloma	   has	   shown	   that	   the	   upregulation	   of	  
these	  miRNAs	   is	   associated	  with	   either	   the	   transformation	   from	  MGUS	   to	  myeloma	   or	  
with	  an	  mRNA-­‐based	  risk	  score.58,90	  In	  this	  study,	  for	  the	  first	  time,	  we	  have	  shown	  that	  a	  
high	   level	   of	   expression	   of	   these	   two	   clusters	   is	   associated	   with	   an	   adverse	   clinical	  
outcome	  in	  a	  series	  of	  well	  characterized	  clinical	  samples.	  
Currently,	   ISS	   plus	   the	   FISH–based	   abnormalities	   are	   used	   to	   define	   prognosis;	  
however,	  this	  approach	  does	  not	  capture	  all	  the	  clinical	  variability	  and	  there	   is	  potential	  
for	   it	   to	  be	   improved.	  By	  combining	   the	  expression	   level	  of	  miR-­‐17	  and	  miR-­‐886-­‐5p,	  we	  
classified	   patients	   into	   three	   subgroups	   associated	   with	   significant	   differences	   in	   OS,	  
which	   were	   retained	   in	   multivariate	   analyses	   when	   taking	   into	   account	   ISS	   and	   FISH–
based	  model.	  Notably,	  when	   the	  miRNA-­‐based	  classifier	  was	   removed	   from	  this	  model,	  
the	   predictive	   power	   was	   significantly	   reduced	   (P	   =	   0.0004).	   	   The	   robustness	   of	   the	  
miRNA-­‐based	   classifier	   has	   been	   validated	   using	   one-­‐thousand	   bootstrap	   replications	  
with	  an	  estimated	  error	  rate	  of	  1.6%.	  Importantly,	  the	  definition	  of	  the	  aggressiveness	  of	  
the	  clinical	  behaviour	  of	  newly	  presenting	  cases	  can	  be	  improved	  by	  the	  incorporation	  of	  
this	  miRNA-­‐based	  classifier	  into	  currently	  used	  strategies.	  In	  this	  context,	  we	  have	  shown	  
that	   within	   the	   group	   classified	   as	   being	   at	   low	   risk	   using	   ISS/FISH	   approach	   the	  
expression	   of	   these	  miRNAs	   can	   define	   a	   further	   group	   (comprising	   half	   of	   the	   cases)	  
with	   a	   significantly	  worse	   clinical	   outcome,	  which	   really	   should	   belong	   to	   intermediate	  
risk	  group.	  The	  miRNA-­‐based	  risk	  classifier	  is	  also	  able	  to	  identify	  prognostically	  important	  
subgroups	  within	  t(4;14)	  cases;	  notably	  the	  t(4;14)	  cases	  with	  low	  expression	  level	  of	  both	  
these	   two	   miRNAs	   show	   prolonged	   median	   OS	   of	   71	   months.	   These	   findings	   are	  
supported	   by	   a	   large	   body	   of	   literature	   showing	   that	   miRNA-­‐based	   classifiers	   predict	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survival	   in	   various	   types	   of	   cancers,	   which	   are	   independent	   from	   currently	   known	  
clinicopathological	   features.50,121-­‐125	   Although	   there	   is	   no	   independent	   validation	  dataset	  
available,	  one	  of	  the	  two	  miRNAs	  comprising	  the	  classifier	  (miR-­‐17)	  was	  associated	  with	  
GEP	  risk	  score;90	  the	  classifier,	  therefore,	  could	  be	  considered	  as	  partially	  validated.	  The	  
other	  miRNA,	  miR-­‐886-­‐5p,	   is	   not	   present	   on	   their	   array.	   The	   classifier	   identified	   in	   this	  
study	  is	  not	  significantly	  associated	  with	  PFS,	  and	  we	  have	  confirmed	  that	  its	  differential	  
effect	  on	  OS	  is	  largely	  due	  to	  the	  impact	  on	  post-­‐relapse	  survival.	  OS	  and	  PFS	  are	  known	  
to	  be	  different	  endpoints;	   therefore,	   the	  strongest	  predictors	   for	  each	  of	   them	  are	  not	  
necessarily	   the	   same.	   Furthermore	   OS	   remains	   the	   gold	   standard	   for	   demonstrating	  
clinical	  benefit	  in	  myeloma	  patients.	  Notably	  the	  oncogenic	  role	  of	  the	  clusters	  mir-­‐17~92	  
and	   mir-­‐106a~363	   in	   myeloma	   has	   been	   well	   demonstrated,58,90	   although	   none	   of	   the	  
members	   is	   associated	   with	   PFS.	   To	   this	   regard,	   it	   could	   be	   conceivable	   that	   the	  
deregulation	   of	   specific	   genes/miRNAs	  might	   have	   long-­‐term	   effects	   on	  myeloma	   cells	  
and/or	   their	   interactions	   with	   other	   environmental	   components,	   which	   might	   not	   be	  
reflected	  by	  PFS.	  Indeed,	  miRNAs	  have	  recently	  been	  recognized	  as	  key	  regulators	  in	  the	  
neoplastic	  microenvironment.126	  	  
An	   important	  question	   is	  whether	   these	  miRNA	  clusters	  are	  biologically	   relevant	  
and	  actually	  mediate	   the	  biological	  changes	  associated	  with	   the	  poor	  prognosis	   in	  MM.	  
Recently,	  two	  studies	  provide	  functional	  evidence	  that	  miRNAs	  within	  mir-­‐17~92	  and	  mir-­‐
106a~363	   clusters	   target	   critical	   genes	   including	  BCL2L11,	   SOCS1	   and	   CDKN1A,	   which	   are	  
known	   to	   be	   involved	   in	   both	   myeloma	   cell	   proliferation	   and	   apoptosis.51,90	   In	   one	   of	  
these	  studies	  the	  oncogenic	  role	  of	  miR-­‐19a/b	  was	  also	  confirmed	  in	  a	  nude	  mice	  model	  in	  
which	   regression	   of	   transplanted	   tumours	   after	   treatment	   with	   an	   antagonist	   was	  
achieved.51	  BCL2L11	   (BIM)	  and	  CDKN1A	   (p21)	  are	  also	   two	  main	  downstream	  effectors	  of	  
TGFβ	  signalling,	  the	  inactivation	  of	  which	  is	  a	  major	  step	  in	  the	  development	  of	  a	  variety	  
of	  human	  tumors.127	  The	  proapoptotic	  genes	  PTEN,	  E2F1,	  and	  anti-­‐angiogenic	  genes	  CTGF,	  
THBS1	  have	  also	  been	  previously	  shown	  to	  be	  targets	  of	  these	  two	  clusters	  of	  miRNAs.108-­‐
111	   In	   our	   study	   we	   observed	   the	   inverse	   correlations	   of	   the	   expression	   level	   between	  
these	  genes	  and	  their	  regulating	  miRNAs,	  suggesting	  that	  an	  important	  interaction	  could	  
also	  exist	  in	  myeloma.	  
The	  association	  of	  mir-­‐17~92	  expression	  and	  copy	  number	  of	  chromosome	  13q	   in	  
MM	   is	  currently	  a	  controversial	   issue.	   In	  keeping	  with	  another	   report,52	  our	  analysis	  did	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not	  identify	  an	  association	  between	  expression	  of	  mir-­‐17~92	  and	  del(13q);	  however,	  a	  few	  
other	  studies	  observed	  an	  at	  least	  partial	  correlation.64,66,67	  This	  discordance	  may	  be	  due	  
to	  the	  variability	  of	  the	  clinical	  samples.	  MYC	  deregulation	  is	   important	   in	  myeloma,128,129	  
and	  recent	  evidence	  suggested	  that	  MYC	  not	  only	  regulates	  expression	  of	  protein-­‐coding	  
genes	   directly,	   but	   also	   controls	   the	   expression	   of	   a	   large	   set	   of	   miRNAs.110,130	   In	  
particular,	  MYC	  upregulation	  has	  been	  shown	  to	  directly	  activate	  the	  miR-­‐17~92	  and	  miR-­‐
106a~363	  clusters,110	  suggesting	  that	  it	  may	  play	  an	  important	  role	  in	  miRNA	  deregulation	  
in	  MM.	  Indeed	  in	  this	  study	  we	  identified	  a	  significant	  positive	  correlation	  between	  MYC	  
expression	   and	   the	   expression	   levels	   of	   individual	   miRNAs	   within	   these	   two	   clusters.	  
Despite	  being	  on	  different	  chromosomes,	  the	  high	  correlation	  between	  miR-­‐17	  and	  miR-­‐
106a	  may	   support	   them	  being	   co-­‐regulated.	  However,	   as	   the	   correlations	   between	   the	  
expression	  of	  MYC	  and	  members	  of	  the	  two	  clusters	  are	  modest	  (R	  value	  up	  to	  0.3),	  other	  
genes	  may	  also	  be	  important	  in	  their	  deregulation.	  mir-­‐17~92	  cluster	  has	  previously	  been	  
shown	  to	  be	  activated	  by	  the	  E2F	  family	  member	  E2F3,131	  and	  E2F	  and	  MYC	  are	  known	  to	  
transactivate	  each	  other,	  suggesting	  a	  possible	  complex	  regulatory	  signal	   for	  miR-­‐17~92	  
expression	   (Figure	   13).	   These	   observations	   also	   highlight	   the	   potential	   importance	   of	  
Myc/E2F/miR-­‐17~92	  negative	  feedback	  loop	  in	  cancer.	  	  
	  
	  
Figure	   13.	  A	  proposed	  model	  of	  miRNA/MYC/E2F	   interaction	  and	  downstream	  targets	   in	  
MM	  (O’Donnell	   et	   al,	   2005;	  Dews	  et	   al,	   2006;	  Novotny	  et	   al,	   2007;	  Pichiorri	   et	   al,	   2008;	  
Xiao	  et	  al,	  2008;	  Zhou	  et	  al,	  2010).	  
	  
The	  deregulated	  genes	  downstream	  of	  the	  deregulated	  miRNAs	  could	  mediate	  the	  
prognostic	  effect	  of	  these	  miRNAs;	  therefore,	  we	  developed	  an	  approach	  to	  identify	  the	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putative	   targets	   of	   miR-­‐886-­‐5p,	   the	   other	   miRNA	   comprising	   the	   classifier.	   The	  
pathogenic	  role	  of	  miR-­‐886-­‐5p	  has	  not	  been	  previously	  reported	  in	  myeloma;	  however,	  it	  
was	  shown	  to	  be	  upregulated	  in	  Burkitt	  Lymphoma	  compared	  to	  some	  other	  lymphoma	  
types.132,133	  MiR-­‐886-­‐5p	   inhibits	  apoptosis	  of	  cervical	  cancer	  cells	  by	  down-­‐regulating	  the	  
production	  of	  Bax.134	  Increased	  miR-­‐886-­‐3p,	  which	  originates	  from	  the	  same	  pre-­‐miRNA,	  
has	   recently	   been	   associated	   with	   chemo-­‐resistance	   in	   bladder	   cancer,	   which	   was	  
translated	   to	   impaired	  overall	   survival.135	  As	   the	   top	   target	   for	  miR-­‐886-­‐5p,	  NR3C1	   is	   the	  
glucocorticoid	   receptor	   gene	   and	   its	   downregulation	   has	   been	   associated	   with	  
glucocorticoid	   resistance	   and	   inferior	   prognosis	   in	   MM;136,137	   the	   association	   of	   the	  
expression	  of	  miR-­‐886-­‐5p	  with	  prognosis	  was	  confirmed	  in	  our	  dataset.	  One	  of	  the	  other	  
potential	  targets	  ICOSLG	  (inducible	  co-­‐stimulator	  ligand)	  is	  expressed	  on	  tumour	  cells	  and	  
has	   been	   reported	   to	   have	   an	   important	   role	   in	   tumor	   immunity;	   it	   also	   induces	   B-­‐cell	  
differentiation	   into	  plasma	  cells.	   It	   has	  been	  demonstrated	   that	   cytotoxic	  T	   cells	  play	  a	  
critical	   role	   in	  myeloma	   cell	   elimination;138,139	   therefore,	   it	   is	   not	   surprising	   that	   ICOSLG	  
expression	  has	  an	  effect	  on	  OS	  of	  myeloma	  patients.	   The	  precursor	  of	  miR-­‐886-­‐5p	  and	  
miR-­‐886-­‐3p,	  previously	  proposed	  to	  be	  a	  vault	  RNA,	  a	  component	  of	   the	  vault	  complex	  
implicated	   in	   cancer	   drug	   resistance,	  was	   recently	   shown	   neither	   to	   be	   a	   genuine	   pre-­‐
miRNA	  nor	  a	  vault	  RNA;140	  miR-­‐886	  binds	  directly	  to	  PKR	  (Protein	  Kinase	  RNA-­‐activated)	  
and	   silencing	   of	   miR-­‐886	   activates	   PKR	   and	   its	   downstream	   pathways,	   eIF2α	  
phosphorylation	   and	   the	   NF-­‐κB	   pathway,	   leading	   to	   impaired	   cell	   proliferation.140	   The	  
association	   of	   miR-­‐886-­‐5p	   expression	   level	   with	   OS	   warrants	   validation	   and	   additional	  
studies	  to	  investigate	  its	  potential	  roles	  in	  MM	  pathogenesis.	  
	  
MM	  is	  a	  genetically	  complex	  disease	  with	  a	  well	  described	  heterogeneity	  in	  clinical	  
outcome.	  Recent	  research	  highlights	  the	  contribution	  of	  a	  new	  class	  of	  non-­‐coding	  genes,	  
miRNA,	   in	   myeloma	   pathogenesis.	   In	   this	   work,	   we	   have	   developed	   a	   2-­‐miRNA-­‐based	  
classifier	   able	   to	   stratify	  MM	  patients	   into	   three	   risk	   groups.	   The	   classifier	   significantly	  
improves	   the	  predictive	  power	  of	  an	  outcome	  predictor	  comprising	   ISS	  and	  FISH-­‐based	  
abnormalities;	   therefore,	   it	   may	   represent	   a	   complementary	   prognostic	   tool	   in	   clinical	  
practice	   after	   being	   validated	   using	   independent	   dataset.	   The	   miRNAs	   related	   to	   the	  
classifier	  are	  biologically	  relevant,	  and	  integrative	  analyses	  indicate	  that	  they	  are	  putative	  
candidates	   regulating	   a	   large	   number	   of	   genes	   involved	   in	   MM	   biology	   such	   as
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proliferation,	  apoptosis,	  angiogenesis	  and	  drug	  resistance.	  In	  this	  context,	  miRNAs	  can	  be	  
built	   into	  molecular	   diagnostic	   strategies	   for	   risk	   stratification	   as	  well	   as	   being	  used	   as	  
treatment	  targets	  in	  MM.	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